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1. ORIGINAL PUBLICATIONS 
 
This thesis is based on the following original publications, which are referred to in the 
text by their Roman numerals (I-IV):  
 
I Khanna A*, Böckelman C*, Hemmes A, Junttila MR, Wiksten J-P, Lundin M, 
Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J**, Ristimäki 
A**: MYC-Dependent regulation and prognostic role of CIP2A in gastric 
cancer. J Natl Cancer Inst. 2009;101(11):793-805. 
 
II Böckelman C, Lassus H, Hemmes A, Westermarck J, Leminen A, Haglund C, 
Bützow R, Ristimäki A: CIP2A is a marker of reduced survival in serous 
ovarian cancer patients. Brit J Cancer 2011;105(7):989-995.  
 
III Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, 
Atula T, Ristimäki A, Haglund C: High CIP2A immunoreactivity is an 
independent prognostic indicator in early-stage tongue cancer. Brit J Cancer 
2011;104(12):1890-1895.  
 
IV  Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C: 
CIP2A overexpression is associated with c-Myc expression in colorectal 
cancer. Cancer Biol & Ther 2012;13(6):Epub ahead of print. 
 
* These authors contributed equally to the study. 
** These senior authors contributed equally to the study. 
 
These original publications (I-IV) have been reprinted here with the kind permission 





Worldwide and notably in the developed countries, cancer is an increasing cause of 
morbidity and mortality, being the second most common cause of death after ischemic 
heart disease. Now and in the future new cancer cases need to be diagnosed earlier. 
Prognostic factors may be helpful in recognizing and handling those patients who 
need more aggressive therapy, and it is also desirable to predict treatment response 
accurately. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein 
predominantly expressed in malignant tissues and inhibiting protein phosphatase 2A 
(PP2A) activity; it is a promising target for cancer therapy. The aim of this thesis was 
to evaluate the prognostic role of CIP2A in solid cancers, and for this purpose to 
explore expression of CIP2A, and investigating regulation of CIP2A in order to gain 
insight into signalling pathways leading to alteration in prognosis.  
 Patients diagnosed with gastric, serous ovarian, tongue, or colorectal cancer at 
Helsinki University Central Hospital were included. Tumour tissue microarrays 
assembled from specimens from these patients were prepared and stained 
immunohistochemically for CIP2A protein expression. Associations with 
clinicopathologic parameters and other biomarkers were explored, and survival 
analyses were done according to the Kaplan-Meier method. Study of the role of 
CIP2A in intracellular signalling in vitro involved gastric, ovarian, and tongue cancer 
cell lines.  
 We found CIP2A to be highly expressed in gastric, ovarian, tongue, and 
colorectal cancer specimens. CIP2A was associated with clinicopathologic parameters 
characterizing an aggressive disease, namely advanced stage, high grade, p53 
immunopositivity, and high proliferation index. CIP2A led to recognition of gastric, 
ovarian, and tongue cancer patients with poor prognosis, however, with a cancer type-
specific cut-off level for prognostic significance. In tongue cancer, it served as an 
independent prognostic marker. In contrast, in colorectal cancer, CIP2A provided no 
prognostic value. In cancer cell lines, CIP2A was highly expressed at both protein and 
mRNA levels, and promoted cell proliferation and anchorage-independent growth. In 
gastric cancer, we demonstrated with a MYCER construct in mouse embryo 
fibroblasts that activation of MYC led to increased CIP2A mRNA expression, and 
hence we suggested that a positive feedback mechanism between CIP2A and MYC 
may potentiate and prolong the oncogenic activity of these proteins. We demonstrated 
in ovarian cancer an association between CIP2A and EGFR protein overexpression 
and EGFR gene amplification. In ovarian and tongue cancer cells we showed that 




 In conclusion, high CIP2A expression occurred frequently among patients 
with aggressive disease. CIP2A may serve as a prognostic marker in gastric, ovarian, 
and tongue cancer and thus may help in tailoring therapy for cancer patients. The 
positive feedback mechanism between CIP2A and MYC, as well as the positive 
regulation of CIP2A by EGFR, are a few signalling pathways regulating and regulated 
by CIP2A. These and other mechanisms need to be studied further, however. CIP2A 
is a potential target for therapy, and its potential role as predictive marker and as a 





AML  Acute myeloid leukaemia 
AMPK  AMP (adenosine monophosphate) activated kinase 
AJCC  American Joint Committee on Cancer 
ATCC  American Type Culture Collection 
cagA  Cytotoxin-associated protein A 
CEA  Carcinoembryogenic antigen 
CI  Confidence interval 
CIP2A  Cancerous inhibitor of protein phosphatase 2A 
DAPk  Death-associated protein kinase 
DMSO  Dimethyl sulphoxide 
DNA  Deoxyribonucleic acid 
DSMZ German collection of Microorganisms and Cell Cultures (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen)  
EGFR  Epidermal growth factor receptor 
EGTM  The European Group on Tumour Markers 
ERBB2 v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2, 
neuro/glioblastoma-derived oncogene homolog (avian) 
ERK  Extracellular signal-regulated kinase  
H&E  Haematoxylin and eosin 
HER-2  Human epidermal growth factor receptor 2  
FOBT  Faecal occult blood testing 
HCC  Hepatocellular carcinoma 
H. pylori Helicobacter pylori 
HR  Hazard ratio 
IARC  International Agency for Research on Cancer 
IHC  Immunohistochemistry 
JNK  c-Jun N-terminal kinase 
LOH  Loss of heterozygosity 
MAPK  Mitogen-activated protein-serine/threonine kinase   
MEK  MAP kinase/ERK kinase 
MEFs  Mouse embryo fibroblasts 
NA  Not applicable 
PI3K  Phosphatidylinositide (PI) 3-kinase 
PBS  Phosphate-buffered saline 
PP2A  Protein phosphatase 2A 
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qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RNA  Ribonucleic acid  
SEM  Standard error of mean 
siRNA  Small interfering ribonucleic acid 
SPF  S-phase fraction 
TBS-NP40 Tris-buffered saline with NP40 (Igepal CA630, Sigma) 
TCF  T-cell factor 
TMA  Tissue microarray 
TNM  Tumour, Node, Metastasis 
TP53  Tumour protein p53 
UICC Union for Cancer Control (Union Internationale Contre le Cancer) 
WB Western blot 








In 2007, over 26 000 persons were diagnosed with cancer in Finland and 41% of these 
died of their disease. Cancer accounts for a large proportion of morbidity and 
mortality and is the second most common cause of death after ischemic heart disease. 
In a national prospect, the Finnish Cancer Registry has estimated by 2020 an 29% 
increase in incidence rate for men and 24% for women, with 17 700 new cancer cases 
diagnosed in men and 16 100 in women, largely explained by the ageing population. 
The age-adjusted overall mortality rate is predicted to decrease by 10 to 20% until 
2020, but with a 13 to 18% increase in the annual number of cancer deaths. Hence, 
cancer diseases are a major public health problem, demanding research in the field.  
 Cancer arises from malignantly transformed cells. The genetic information is 
stored in the genome in chromosomes, which are copied in the process of cell 
proliferation and differentiation. Cancer may arise from mistakes in this copying 
process as the result of an incorrect genome. Hanahan and Weinberg (2000, 2011) 
have proposed six hallmark capabilities of cancer: sustaining proliferative signalling, 
evading growth suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis, and resisting cell death.  
Prognostic factors are defined as “variables that can account for some of the 
heterogeneity associated with the expected course and outcome of a disease” but in 
the epidemiological literature, the term prognostic factor is commonly reserved for “a 
probability of future event in patients who currently have a disease” (Gospodarowicz 
et al. 2001). The term predictive factor commonly refers to “prognosis for a 
measurable response” following a treatment intervention, whereas the term prognostic 
factor stands for a more narrow context with the end-points probability of cure or 
prolongation of survival (Gasparini et al. 1993, Henderson and Patek 1998). Today, 
the term predictive marker is used for biomarkers that provide information as to 
whether patients are likely to benefit from a specific therapy (Walgren et al. 2005, 
Duffy et al. 2011). This is in contrast to prognostic markers, which “allow the natural 
course of a specific disease to be predicted”, or in other words differentiate between 
patients with a good versus a poor prognosis (Sawyers 2008, Duffy et al. 2011). In 
most cancers even today, tumour-stage classification is the prognostic factor most 
commonly used. Although numerous biomarkers have undergone evaluation for a 
prognostic role, only a few serve as predictive markers in clinical practice. Mackillop 
states, that “To be relevant to the clinical practice, prognostic factors must either have 
a significant impact on cancer outcome, or be used to select treatment methods” 
(Gospodarowicz et al. 2001). To improve the predictive value and clinical usefulness 
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of biomarkers, cancer-specific prediction models may prove useful, which include 
several predictive factors, together with common clinicopathologic parameters.  
Tumour markers are divided into serum markers, tissue-based markers, and in 
colorectal cancer also stool-based markers (Duffy et al. 2007). Serum markers mainly 
serve in postoperative surveillance, whereas tissue-based markers may serve as 
potential prognostic or predictive markers. Stool-based markers have proven 
beneficial in trials screening for colorectal cancer, but their definitive role in clinical 
practice remains to be discussed. 
To improve the prognosis of cancer patients, tumours must be diagnosed at an 
early stage. Tumour markers may allow detection of cancer in its early course, hence 
improving prognosis and survival, and possibly allowing selection of patients who 
would benefit from adjuvant treatment. TNM (Tumour Node Metastasis) -staging of 
tumours is commonly used in planning of tumour treatment and prognosis. 
Prognostication based on the TNM-stage classification by the World Health 
Organization (WHO) and the International Agency for Research Against Cancer 
(IARC) is today insufficient, however, and new prognostic markers are still needed.  
When this thesis project began, the first publication addressing the role of the 
oncoprotein, called cancerous inhibitor of protein phosphatase 2A (CIP2A; PP2A), 
had just appeared (Junttila et al. 2007). Since then, several authors have addressed the 
functional and clinical role of CIP2A in cancer. To date, CIP2A has been studied 
mostly in carcinomas, but a few studies address its role also in haematological 
malignancies (Lucas et al. 2011, Wang et al. 2011) and non-malignant diseases (Lee 
et al. 2011). In general, CIP2A is expressed at low levels or not at all in normal 
tissues, whereas in malignant tissues, CIP2A expression frequency has been high.  
This thesis addresses the prognostic role of cancerous inhibitor of protein 
phosphatase (CIP2A) in gastric, colorectal, tongue, and ovarian cancer. It also 
investigates associations between CIP2A expression and clinicopathologic factors, 
and the regulation of CIP2A expression in cancer cells.  
Review of the literature 
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5. REVIEW OF THE LITERATURE 
 
5.1. Gastric cancer 
5.1.1.  Epidemiology and etiology 
During the past five decades, gastric cancer incidence in Finland has declined; 
formerly one of the most common cancers, in 2007 it was the 11th most common 
cancer in men, and 14th in women, accounting for only 5% of all deaths from cancer 
(Finnish Cancer Registry 2009). Worldwide, however, gastric cancer is still the 
second most common cause of cancer deaths (Jemal et al. 2011). Its declining 
incidence in Finland and in the world follows primarily the declining incidence of 
Helicobacter pylori (H. pylori), better hygiene, and less crowded living. Worldwide, 
the incidence is high in eastern Asia, and in central and eastern Europe, conversely, in 
North America and most African countries, incidence is low (Jemal et al. 2011). 
Gastric cancer is twice as common in men, and more common in the lower social 
classes (Weiderpass and Pukkala 2006, Nagel et al. 2007). In Finland in 2007, the 
age-adjusted incidence rate for men was 7.8/100 000 personyears and for women 
4.6/100 000 personyears (Figure 1) (Finnish Cancer Registry 2009). 
 Gastric cancer includes the more common non-cardia cancer and cardia 
cancer; for these, etiology and clinical manifestation differ. Risk factors for are 
mainly environmental. H. pylori is, by the International Agency for Research on 
Cancer (IARC), classified as a class 1 carcinogen (The Eurogast Study Group, 1993, 
IARC 1994). Patients positive for H. pylori have a 3- to 6-fold greater risk for 
developing non-cardia gastric cancer, especially if positive for the H. pylori virulence 
factor cagA (IARC 1994, Blaser et al. 1995, Palli et al. 2007, Bornschein et al. 2009). 
In contrast, no association has been detectable between cardia cancer and H. pylori. 
Smoked and salted food have been considered risk factors (Tsugane and Sasazuki 
2007), and high intake of fruit and vegetables, considered protective (Huang et al. 
2000). Large prospective studies have, however, failed to confirm this association 
(Gonzalez et al. 2006, Freedman et al. 2008b, Key 2011). Results from studies 
conducted to assess the role of smoking and high alcohol intake vary (Dicken et al. 
2005, Shang and Pena 2005). In contrast to non-cardia cancer, smoking and obesity 
are in cardia cancer established risk factors (Donohoe et al. 2010).  
Review of the literature 
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Figure 1. Cancer incidence and mortality in Finland. A) Age-adjusted incidence rates in 1961-
2007 for men and B) women. C) Age-adjusted mortality rates in 1961-2007 for men and D) 
women. Adapted from the Finnish Cancer Registry, 2009.  
 
5.1.2. Pathogenesis and diagnosis 
Gastric cancer is believed to arise partly as a consequence of chronic atrophic gastritis 
induced by H. pylori infection. Chronic inflammation predisposes to development of 
atrophic gastritis, which may induce intestinal metaplasia, and later dysplasia (Correa 
and Houghton 2007). The less acidic environment arising in atrophic gastritis allows 
bacteria producing nitrites and carcinogenic N-nitroso compounds to colonize the 
gastric mucosa, predisposing to genetic alterations.  
Of gastric tumours, 90% are adenocarcinomas, of which 40% are localized to 
the pylorus and antrum, 40% to the corpus and fundus, and the rest to the cardia area. 
Histologically, according to the WHO, the five main types of adenocarcinoma are 
tubular,	  papillary, mucinous, and poorly cohesive (including signet-ring cell type), 
and mixed carcinomas (Bosman et al. 2010). According to Laurén’s classification, 45 
to 60% are of intestinal type and usually associate with H. pylori positivity, distal 
location, and liver metastasis (Laurén 1965). The diffuse type gastric cancer, on the 
other hand, is believed to arise spontaneously without any predisposing chronic  
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atrophic gastritis and intestinal metaplasia, and is usually marked by a lack of tubular 
structure and by metastasis to lymphatic vessels and the lungs. TNM-stage 
classification by the WHO/IARC is still today the most important prognostic factor, 
because tumours limited to the serosa show lymphatic infiltration in only 18% of the 
cases, whereas tumours penetrating the serosa present with distant metastasis in 80% 
of the cases (Table 1). 	  
The fact that symptoms are unspecific and relatively few leads to late 
diagnosis. Common but unspecific symptoms are weight loss (70 to 80% of the 
patients), epigastric pain (70%), and anaemia. Dysphagia arises in the advanced stage 
of cardia cancer when over 80% of the lumen is occluded. Symptoms of retention and 
nausea can be the result of tumours in the pyloric area. No single blood test for 
screening or diagnosis is available. Carcinoembyronic  antigen (CEA) is positive in 
18% of the gastric cancer patients, but 50% are false positives, whereas CA 19-9 is 
more specific, but usually implies metastasized disease (Roberts et al. 1989). 
Louhimo et al. (2004) found that human chorionic gonadotropin (hCGβ) and CA 72-4 
serve as independent prognostic markers, whereas CA 19-9 and CA 242 are 
dependent prognostic factors. Usually diagnosis is reached by gastroscopy, for which 
sensitivity is high. Computed tomography is utilized for clinical staging prior to 
surgery; however, sometimes diagnostic laparoscopy is necessary to confirm the 
extent of the disease.  
5.1.3. Treatment 
The only curative treatment is radical surgery with subtotal or total gastrectomy 
(Heberer et al. 1988). In D1-lymph node dissection, perigastric lymph nodes are 
removed and in D2, the lymph node dissection is extended to the surrounding arteries. 
In D3, distant lymph nodes in areas surrounding the hepatic portal and the abdominal 
aorta undergo dissection in addition to the local lymph node dissection (Siewert et al. 
1998, Bonenkamp et al. 1999, Cuschieri et al. 1999). The 15-year follow-up in the 
Dutch Gastric Cancer Trial (DGCT) showed that gastric-cancer-related death and 
locoregional recurrence were significantly greater in patients who underwent D1 
lymphadenectomy than for those in the D2 group (Songun et al. 2010). Disadvantages 
with D2 resection were high postoperative mortality, complications, and reoperation 
rates; however, D2 resection with a spleen and pancreas-preserving technique has 
proven safer and recommendable (Wang et al. 2004, Yu et al. 2006). In Japan, where 
more radical surgery has been adopted, prognosis is better (Maruyama et al. 1996).  
 The INT0116 randomized controlled trial (Macdonald et al. 2001) showed that 
surgery together with postoperative chemoradiotherapy is beneficial when compared 
to surgery alone. Their result has been criticized, however, for inadequate lymph node 
dissection. Sakuramoto et al. (2007) later showed that for stage II/III patients after D2 
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dissection, the chemotherapeutic agent S-1 improves survival. Treatment modalities 
differ between Western and Asian centres, and Kurokawa and Sasako (2008) suggest 
that surgery with D2 lymph node resection alone is superior to D1 dissection in 
combination with chemoradiotherapy. The MAGIC (Medical Research Council 
Adjuvant Gastric Infusional Chemotherapy) trial demonstrated that perioperative 
chemotherapy, with epirubicin, cisplatin, and infused fluorouracil (ECF) administered 
in three preoperative and three postoperative cycles, is preferable to surgery only 
(Cunningham et al. 2006).  Bang et al. (2010) reported recently that for patients with 
advanced gastric cancer positive for human epidermal growth factor receptor 2 (HER-
2), trastuzumab, a monoclonal antibody against HER-2, in combination with 
chemotherapy significantly improved survival compared to survival with 
chemotherapy alone.  
5.1.4. Prognosis 
The age-standardized 5-year gastric cancer-specific relative survival ratio was, in 
2005-2007, 25% for men and 28% for women (Finnish Cancer Registry 2009). In 
over half the cases, gastric cancer is found in its advanced stage (pT3-T4). Median 
survival for patients with T3 disease is 12 months and for those with T4 disease only 
6 months (Victorzon 1996).  
 
5.2. Ovarian cancer 
5.2.1. Epidemiology and etiology 
Ovarian cancer is the second most common gynaecological cancer, after endometrial 
cancer. In 2007, it was the 5th most common cancer in women in Finland with an 
incidence rate of 8.4/100 000 personyears (Figure 1) (Finnish Cancer Registry 2009). 
Ovarian tumours are classified as common epithelial tumours, which constitute the 
majority, as sex cord stromal tumours, and germ cell tumours. They originate from 
the embryonic Müllerian epithelium, which in addition gives rise to the Fallopian 
tubes, the epithelium of the corpus and cervix of the uterus, and the proximal part of 
the vagina. Hence, Dubeau (2008) has proposed that the Fallopian tubes represent the 
normal tissue that is equivalent to ovarian tumour tissue. The risk for developing 
ovarian cancer is greatest among those belonging to families with germline mutations 
in the BRCA1- or BRCA2-genes or having ovarian cancer cases among close relatives. 
Increased risk has been demonstratable among infertile and nulliparous women (Risch 
et al. 1994). According to the ovulation hypothesis proposed by Fathalla (1971), a 
greater number of ovulatory cycles (more than 40 years of ovulation, late menopause) 
leads to increased risk for ovarian cancer because ovarian surface epithelial cells are 
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more prone to develop mutations in the frequent repair of the ovarian surface. The 
gonadotropin stimulation theory, on the other hand, states that  stimulation of the 
ovarian surface epithelium by fertility drugs may increase the risk in infertile women 
of developing epithelial ovarian cancer (reviewed in Landen et al. 2008). The greater 
incidence of ovarian cancer in Western countries is illustrated by a high living 
standard and more frequent obesity (Lane 2008, Bettochi et al. 1982).  
5.2.2. Pathogenesis, screening, and diagnosis 
Epithelial ovarian tumours are grouped into serous, mucinous, endometrioid, clear 
cell, transitional cell, mixed epithelial, and undifferentiated tumours. The abundance 
of different types lies in their mutual origin in the Müllerian system. Serous 
cystadenocarcinomas constitute the majority (40 to 50%) of ovarian cancers and 
endometrioid carcinomas, and mucinous cystadenocarcinomas are common (10 to 
20% each). Ovarian tumorigenesis has been proposed to evolve through low- and 
high-grade pathways: type-I tumours are characterized by their low-grade serous, 
mucinous, endometrioid, and clear cell carcinoma type, whereas type-II tumours are 
characterized by high-grade serous and undifferentiated carcinomas (Shih and 
Kurman 2004, reviewed in Landen et al. 2008, Levanon et al. 2008). Low-grade type-
I tumours are believed to arise through precursor lesions, with frequent mutations in 
BRAF and KRAS genes (Singer et al. 2003a, b). In contrast, high-grade type II 
tumours develop without precursor lesions and commonly overexpress ERBB2 (Ross 
et al. 1999, Lassus et al. 2006) and AKT (Cheng et al. 1992), and harbour mutations 
in the TP53 gene (Singer et al. 2005).  
Ovarian tumours rarely give rise to specific symptoms. The currently available 
methods for screening (clinical examination, intravaginal ultrasonography, and 
tumour markers) are unsuitable for population-based screening (Clarke-Pearson 2009, 
Daly et al. 2010, Schorge et al. 2010, reviewed in Cragun 2011). Diffuse abdominal 
symptoms, lack of appetite, and general fatigue are the initial symptoms. In a 
progressed disease, symptoms may appear in neighbouring organs, leading to frequent 
micturition, urinary urgency, constipation, and dyspareunia. Diagnosis is achieved by 
gynaecological examination, radiological findings, and tumour markers; final 
diagnosis is, however, achieved only by histological verification. 
Staging is established by surgery together with cytological and histological 
examination (Table 2; AJCC 2002, IARC 2002, Tavassoli and Devilee 2003). Local 
spread in the abdominal area is common, although the disease can remain 
asymptomatic. Ovarian cancer metastasizes through the lymphatic vessels; 
haematogenic spread of the disease is uncommon, seen possibly in the late stage of 
the disease.  
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adjuvant treatment to evaluate treatment effects. In 1990, Young et al. concluded that 
adjuvant treatment with melphalan is of no benefit for patients with stage Ia or Ib 
disease with well-differentiated or moderately well-differentiated histological 
characteristics. A recent study targeted a study population of high-risk early-stage 
ovarian cancer patients (stage IA and IB grade 3 [or clear cell], stage IC, or stage II) 
(Mannel et al. 2011). The study-arm received intravenous paclitaxel and carboplatin 
together with a maintenance protocol with paclitaxel weekly for 24 weeks, and the 
control arm, intravenous paclitaxel and carboplatin only, without the maintenance 
paclitaxel. No improvement occurred in recurrence-free survival, but patients 
receiving the maintenance paclitaxel showed adverse toxicity. In advanced-stage 
ovarian cancer, intravenous paclitaxel and cisplatin has become the gold standard 
oncological treatment (McGuire et al. 1996, Bell et al. 2006, reviewed in DiSaia and 
Bloss 2003, Darcy and Birrer 2010). High-dose intraperitoneal cisplatin has shown 
additional benefits in combination with intravenous paclitaxel and carboplatin 
(Markman et al. 2001). This work was continued by Armstrong et al. (2006), who 
showed that intraperitoneal cisplatin and paclitaxel in combination with intravenous 
paclitaxel improves survival. The addition of a third cytotoxic agent to the standard 
paclitaxel and cisplatin regimen provided no improvement in survival (Bookman et al. 
2009). Several on-going trials have been designed to evaluate more effective 
treatment modalities (Darcy and Birrer 2010). Radiotherapy cannot be targeted 
towards the local spread to the abdominal cavity without considerable side-effects, 
and hence is not a useful treatment for ovarian cancer.  
5.2.4. Prognosis 
Age-standardized ovarian cancer-specific 5-year survival in Finland was 49% in 
2005-2007 (Finnish Cancer Registry 2009). This survival rate is relatively high for 
early-stage ovarian cancer patients, however. Because the majority are diagnosed at a 
late stage, overall survival remains poor (Jemal et al. 2008). Several clinicopathologic 
features are recognizable as prognostic factors. Among these are residual tumour size, 
histological subtype, stage (according to FIGO; the International Federation of 
Gynecology and Obstetrics), grade, tumour ploidy, and presence of ascites; however, 
probability models taking several factors into account seem most important 
(Friedlander 1998). 
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5.3. Tongue cancer 
5.3.1. Epidemiology and etiology 
Among the head and neck cancers, lip cancer, and cancers in the oral cavity 
(including tongue cancer) are the most common. In Finland, the most common 
location of cancers in the oral cavity is the tongue (Mäkitie et al. 2007). In 2007, the 
incidence rate of tongue cancer in Finland was for men 1.6/100 000 personyears, and 
for women 1.0/100 000 personyears (Figure 1) (Finnish Cancer Registry 2009). 
Smokers are at substantially increased risk for developing oral cancer, as are those 
with a high intake of alcohol. For smokers with a high intake, risk is even further 
increased (Blot et al. 1988). A significantly lower risk for oral cancer has been 
suggested among those with a relatively high fruit and vegetable intake (Boeing et al. 
2006, Freedman et al. 2008a). This association, however, may relate to residual 
confounding with tobacco and alcohol (Key 2011). Leukoplakia, erytroplasia, and 
lichen ruber planus are precancerous conditions, which may develop into oral 
carcinoma if not recognized and treated early.  
5.3.2. Pathogenesis and diagnosis 
Oral cancer is thought to develop through epithelial dysplasia, where mild, moderate, 
or severe dysplasia may further evolve into carcinoma (Lippman et al. 2005). In the 
multifocal process, the concept of so-called “field cancerization” becomes important, 
implying that the entire area is exposed to the same carcinogens such as alcohol and 
tobacco, which increases the risk for accumulation of genetic alterations and hence, 
for malignant transformation (Slaughter et al. 1953, Califano et al. 1996, Braakhuis et 
al. 2003, Choi and Myers 2008).  
The mobile, proximal two-thirds of the tongue in the oral cavity is commonly 
referred to as the oral tongue, whereas the posterior third belongs to the oropharynx. 
Squamous cell carcinomas constitute 90% of all malignant tumours in the oral cavity, 
which, according to WHO, are divided into verrucous, basaloid squamous cell, 
papillary squamous cell, spindle cell, acantolythic squamous cell, adenosquamous 
carcinomas, and carcinoma cuniculatum (Barnes et al. 2005). Other rare neoplasms 
are lymphoepithelial carcinomas, salivary gland tumours, soft tissue tumours, 
haematolymphoid tumours, and mucosal malignant melanoma. At first presentation, 
the only symptom may be a painless lesion which does not heal completely or a 
metastatic neck tumour without evidence of a primary tumour in the oral cavity. In 
Finland, however, the majority of oral tongue cancers are diagnosed at a relatively 
early stage (T1-T2) (Mäkitie et al. 2007). Results on survival of young tongue cancer 
patients are conflicting. Popovtzer et al. (2004) conclude that overall survival is 
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similar among patients younger than 45 years and among those over 45. Nevertheless, 
they suggest that two different patient groups can be recognized among the young: 
those with an aggressive disease and high mortality within two years, and others with 
an indolent disease. Atula et al. (1996), on the other hand, found no differences in the 
clinical course or prognosis of tongue cancer patients under 40. 
 Tongue cancer is generally regarded as a potentially aggressive disease, as 
even small tumours may metastasize (Keski-Säntti et al. 2007). Mäkitie et al. (2007) 
found in a Finnish cohort that 31% of the patients with an early-stage disease (I-II) 
presented with locoregional recurrence. The TNM classification of oral carcinomas is 
presented in Table 3.  
5.3.3. Treatment 
In Finland in 1995-1999, 97% of the oral tongue cancer patients underwent surgery, 
together with an ipsilateral neck dissection in 51% of the cases and a bilateral neck 
dissection in 4% (Mäkitie et al. 2007). Adjuvant treatment with radiotherapy was 
chosen for 58% of the cases, of which the majority had advanced-stage (III-IV) 
disease. Elective neck dissection has proven beneficial for early-stage tongue cancer 
patients (Keski-Säntti et al. 2006). Laramore et al. (1992) found no advantage of 
chemotherapy for patients with low risk for recurrence, whereas patients with high-
risk disease characteristics (two or more positive regional nodes, extracapsular growth, 
positive margins of resection) may benefit from it (Forastiere et al. 2001). For patients 
with stage III or stage IV disease, recommended standard care is chemotherapy in 
combination with radiotherapy (Forastiere et al. 2001, Finnegan et al. 2009, Pederson 
et al. 2010).    
5.3.4. Prognosis 
In Finland, tongue cancer-specific 5-year survival was 64% in 1995-1999 (Mäkitie et 
al. 2007). Mean disease-specific survival for patients under 60 was 96 months, 
compared to 80 months for patients over 60. The role of tumour thickness and depth 
of infiltration as prognostic factors remains contradictory (Keski-Säntti et al. 2007, 
Woolgar 2006). pT-stage, however, demonstratably predicts local recurrence (Keski-
Säntti et al. 2007).   
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5.4. Colorectal cancer 
5.4.1. Epidemiology and etiology 
In Finland, colorectal cancer is the second most common cancer in men, and the third 
in women. Worldwide, incidence varies, being high in Western countries. In 2007, the 
incidence rate of colon cancer for men was 15.4/100 000 personyears, and for women 
12.4/100 000 personyears (Finnish Cancer Registry 2009). The respective figures for 
rectal, rectosigmoid, and anal cancer was 11.6/100 000 for men and 7.1/100 000 for 
women (Figure 1). For colorectal cancer, a rising trend in incidence rate is observable 
in countries with a previously low incidence, such as Spain and Japan. A decreasing 
trend in incidence is evident in developed countries as a result of earlier diagnosis and 
improved treatment (Jemal et al. 2011, Center et al. 2009a, b). Risk factors for 
colorectal cancer relate mostly to life style. Dietary fibre has been suggested to reduce 
the risk for colorectal cancer, however, large prospective studies have shown that a 
high intake of fruits and vegetables reduces the risk only marginally (Key 2011). 
Recent meta-analyses have demonstrated a modest association between obesity and 
colorectal cancer (Donohoe et al. 2010, Moghaddam et al. 2007). Smoking is a well-
known risk factor for adenomatous polyps, regarded as precursor lesions for 
colorectal cancer (Botteri et al. 2008b). In addition, smoking elevates significantly the 
risk for colorectal cancer, as well as the risk for death from colorectal cancer (Botteri 
et al. 2008a). 
5.4.2. Pathogenesis, screening, and diagnosis 
Colorectal cancer arises through benign neoplasms, adenomas, which can develop 
into dysplasias and later, into carcinomas (Vogelstein et al. 1988). In the beginning of 
colorectal carcinogenesis, adenomatous polyposis coli (APC) -gene inactivating 
mutations lead to deregulated WNT signalling, and β-catenin accumulates 
intracellularly. Hence, proliferating and undifferentiated cells at the bottom of colonic 
crypts fail to migrate upwards and may generate an adenomatous polyp. In addition, 
activating KRAS mutations may develop later in the adenoma-carcinoma sequence, 
causing cells to grow more aggressively (Figure 2) (Grady and Markowitz 2002, 
Pritchard and Grady 2011). In colorectal cancer, 18q loss of heterozygosity (LOH) is 
frequently altered and found to induce malignant transformation (Popat and Houlston 
2005). Petrova et al. (2008) report, that PROX1, a transcription factor that is a target 
of the β–catenin/T-cell factor (TCF) pathway, is an important factor in progression to 
severe dysplasia, and thus its targeted silencing may prevent development of 
subsequent colorectal carcinoma. In carcinomas, several aberrations in signalling 
pathways have been detected (PIK3CA, TP53, TGFBR2, SMAD4), but few have  
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or endoscopic stents may be indicated to prevent gastrointestinal emergencies such as 
obstruction or perforation. 
Adjuvant treatment with an oxaliplatin-based regimen has proven beneficial 
for stage III colon cancer patients in the MOSAIC (Multicenter International Study of 
Oxaliplatin/5-Fluorouracil/Leukovorin in the Adjuvant Treatment of Colon Cancer) 
study (Andre et al. 2009) and in the NSABP (National Surgical Adjuvant Breast and 
Bowel Project) C-07 protocol (Kuebler et al. 2007, reviewed in Gangadhar et al. 2010, 
Lombardi et al. 2010, Silvestris et al. 2010). In a recent Cochrane systematic review, 
disease-free survival was significantly better for those stage-II colon cancer patients 
who received adjuvant treatment (Figueredo et al. 2008). In cases of metastasized 
disease, the KRAS mutation aids in recognizing patients who fail to benefit from 
treatment with epidermal growth factor receptor (EGFR) -targeted antibodies 
(Karapetis et al. 2008). 
5.4.4. Prognosis 
The age-standardized 5-year colon cancer-specific relative survival ratio was, in 
2005-2007, according to the Finnish Cancer Registry, 80% for men and 63% for 
women, and the corresponding figures were 57% for men and 61% for women with 
rectosigmoid, rectal, and anal cancers (Finnish Cancer Registry 2009). The 5-year 
survival for patients with Dukes A disease was 90% at the Department of Surgery, 
Helsinki University Central Hospital in 1982-1998, for Dukes B 75%, for Dukes C 
50%, and for Dukes D below 10% (Carpelan-Holmström 1996, Louhimo 2003). 
 
5.5. Protein phosphatase 2A (PP2A) 
Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that 
widely regulate phosphatase activity in cells. This enzyme consists of a 65 kDa 
scaffolding subunit, termed PR65 or the A subunit, and a catalytic subunit (PP2AC) 
with a molecular mass of 36 kDa, together forming the core dimer (PP2AD). In 
association with four different families of B regulatory subunits (B, B’, B’’, and B’’’), 
PP2A binds to various target proteins. The diversity of subunit isoforms creates 
altogether at least 75 different PP2A holoenzyme compositions, all with different 
cellular and subcellular localization, as well as specific target proteins (Janssens and 
Goris 2001).   
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5.6. Cancerous inhibitor of PP2A (CIP2A) 
CIP2A, cancerous inhibitor of protein 2A, encoded by the gene KIAA1524 and 
located in the 3q13.13 human chromosome region, was first recognized as the p90 
auto-antigen in hepatocellular carcinoma (Soo Hoo et al. 2002). Soo Hoo et al. 
demonstrated its localization to the perinuclear regions of the cytosol, which was later 
confirmed by Junttila et al. (2007). In this first study, the strongest expression of 
p90/CIP2A appeared in mouse embryonic liver specimens, but high expression was 
also noted in the brain, in muscle fibres, and in epidermal layers. Auto-antibodies 
against p90/CIP2A were detectable in sera from patients with hepatocellular 
carcinoma (22%, n = 95), and in a few samples from gastric (3%) and oesophageal 
cancer patients (5%), but not in colon cancer samples. In gastric cancer specimens, 
CIP2A was expressed predominantly in the cytoplasm (Soo Hoo et al. 2002).  
In a subsequent study from the same laboratory, auto-antibodies to p90/CIP2A 
occurred in 31% of 133 prostate cancer patients, significantly more than in the 
previous study and high compared to rates in benign prostate hyperplasia patients (2%, 
n = 68) (Shi et al. 2005). Junttila et al. (2007) recognized p90 as an oncoprotein 
inhibiting PP2A-mediated dephosphorylation of MYC and renamed it cancerous 
inhibitor of PP2A. They showed that CIP2A targets the PR65 scaffolding subunit of 
protein phosphatase 2A, whereby the phosphatase activity of PP2A towards MYC 
serine 62 (S62) is inhibited. The phosphorylated active MYC stimulates cell 
proliferation and transformation (Figure 3). Depletion of CIP2A leads to 
downregulation of MYC both at mRNA and protein expression levels, which is 
unrelated to cell-cycle progression. Furthermore, downregulation of CIP2A reduces 
dense foci formation of HeLa cells in monolayers, as well as reduces anchorage-
independent growth in soft agar. Interestingly, upregulation of CIP2A in head and 
neck squamous cell carcinoma cells and in mouse embryonal fibroblasts leads to 
increased tumour growth. In clinical samples, CIP2A mRNA is expressed at very low 
levels in non-malignant tissues, with the exception of bone marrow, prostate, testis, 
cerebellum, and brain. Overexpression of CIP2A protein can be noted in head and 
neck squamous cell carcinoma specimens, with predominant cytoplasmic localization 
and only weak nuclear expression, whereas in colon cancer, CIP2A mRNA is 
significantly overexpressed when compared to control specimens. Junttila et al. 
(2007) concluded that CIP2A is an oncoprotein important for maintaining the 
malignant cellular phenotype.  
CIP2A functions as a downstream target in the RAS signalling pathway and 
may be induced, in combination with inhibition of the TGF-β tumour suppressor 
pathway, in premalignant head and neck squamous cell lesions (Junttila et al. 2007, 
Junttila and Westermarck 2007). In gastric cancer, Zhao et al. (2010) studied the role 




Figure 3. CIP2A-mediated stabilization of MYC. Reprinted with permission from Prof. J. 
Westermarck (Junttila and Westermarck 2007). 
!
of cagA-positive H. pylori in CIP2A expression, and found that the CagA-induced 
upregulation of CIP2A is mediated through the MEK/ERK pathway. Furthermore, 
Khanna et al. (2011) showed MEK1/2 and EGFR inhibitors to deplete CIP2A 
expression, whereas activation of the MEK1/2-ERK signalling pathway stimulates 
CIP2A expression. They established the ETS1 transcription factor as the mediator of 
the EGFR-MEK1/2-ERK-induced positive regulation of CIP2A and concluded that 
CIP2A overexpression is dependent on the EGFR-MEK1/2-ETS1 signalling pathway. 
CIP2A may promote malignant growth by reducing cell death-associated 
protein kinase (DAPk)-induced apoptosis via the UNC5H2-receptor (Gozuacik and 
Kimchi 2006, Guenebeaud et al. 2010). DAPk serves as a tumour suppressor protein 
by inducing apoptosis and cell death upon activation by dephosphorylation. Netrin-1 
is a diffusible laminin-related protein, which serves in several cell-regulating 
mechanisms and functions as a ligand for the UNC5H2 (also called UNC5B) 
dependence receptor. In the absence of netrin-1, the UNC5H2-receptor recruits PP2A 
to dephosphorylate and hence activates DAPk and induces apoptosis. Guenebeaud et 
al. (2010) demonstrated that netrin-1 favours the recruitment of CIP2A to this 
UNC5H2-DAPk complex, whereby PP2A-mediated dephosphorylation of DAPk is 
inhibited which leads to increased cell survival.  
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In hepatocellular carcinoma (HCC), a role has been proposed for CIP2A in 
causing resistance to the chemotherapeutic drug bortezomib (Chen et al. 2010). In 
HCC cells with high CIP2A expression, the PP2A inhibition, which is mediated by 
CIP2A, inactivates AKT and hence induces apoptosis of HCC cells.  Chen et al. 
further suggested that CIP2A may serve as a predictive factor for bortezomib 
resistance. In a subsequent study, the same group showed that a combination of 
bortezomib together with radiotherapy is even more efficient in reduction of tumour 
growth (Huang et al. 2011). They suggest that the enhancement of radiosensitivity by 
bortezomib in solid tumour cells is dependent on CIP2A expression. In lung cancer 
cells, Ma et al. (2011) demonstrated that rabdocoetsin B, a novel natural compound 
extracted from a Chinese medicinal herbal Rabdosia coetsa, inhibits CIP2A at mRNA 
level, resulting in downregulation of both CIP2A and pAKT proteins. They propose 
that the inhibition of the CIP2A-AKT pathway by rabdocoetsin B in lung cancer cells 
leads to reduced proliferation and induced apoptosis. Interestingly, Choi et al. (2011) 
demonstrated in breast and colon cancer cells that high CIP2A expression is, in 
addition, associated with doxorubicin resistance, suggesting that mutation of p53 
inhibits the doxorubicin-mediated downregulation of CIP2A protein. Growth arrest 
and reduced clonogenic capabilities of tumour cells induced by CIP2A depletion, 
however, are independent of p53 and pRB signalling pathways (Li et al. 2008).  
 
5.7. Clinical role of CIP2A 
CIP2A is overexpressed in in several solid cancers. In gastric cancer, CIP2A mRNA 
has been expressed at a significantly higher level in 87% of 37 gastric cancer 
specimens compared with corresponding adjacent tissue (Li et al. 2008), and in breast 
cancer it is overexpressed in 159 specimens compared with normal breast tissue 
(Come et al. 2009). In non-small-cell lung cancer, CIP2A mRNA has been 
overexpressed in 83% and CIP2A protein in 72% (Dong et al. 2010), whereas Ma et 
al. (2011) found CIP2A mRNA to be overexpressed in 67% and high CIP2A 
immunoreactivity in 67% of the lung cancer specimens studied. In oral squamous cell 
cancer, Katz et al. (2010) demonstrated strong intensity of CIP2A protein in all 8 
carcinoma specimens. Cytoplasmic CIP2A immunopositivity has occurred in 90% of 
40 in oesophageal squamous cell (Qu et al. 2010) and in 97% of 59 prostate 
carcinoma specimens (Vaarala et al. 2010). In cervical cancer, of 72 specimens, 53% 
were immunopositive for CIP2A (Liu et al. 2011a).  
In breast cancer, CIP2A is associated with aggressive disease characteristics 
(Come et al. 2009), whereas in non-small-cell lung cancer, CIP2A expression is 
associated with high proliferation index, but not with any other clinicopathologic 
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parameters (Dong et al. 2010). In renal cell cancer, immunopositive CIP2A is 
associated with advanced disease, high grade, and clear cell type (Ren et al. 2011). 
This is in contrast with the recent results by Liu et al. (2011a) in cervical cancer, 
which showed no association between CIP2A expression and proliferation index, 
tumour size, differentiation status, node metastasis, nor clinical stage. CIP2A is more 
frequently expressed in prostate cancer specimens than in benign prostate hyperplasia 
and associates with high Gleason score (> 7) (Vaarala et al. 2010). In dysplastic oral 
lesions, strong CIP2A expression is evident in the basal and parabasal cell layers 
(Katz et al. 2010). A prognostic role for CIP2A has been demonstrated in lung (Dong 
et al. 2010, Xu et al. 2011) and renal cell (Ren et al. 2011) cancer, in both of which 
CIP2A showed independent prognostic value. In breast cancer, on the contrary, no 
prognostic significance has been apparent (Come et al. 2009).  
CIP2A is present in cervical intraepithelial neoplasia (CIN) III and cervical 
cancer, but not in normal tissues or CIN I and II, suggesting a potential role for 
CIP2A as a diagnostic marker to improve cytological diagnosis for cervical cancer 
(Liu et al. 2011a). Furthermore, CIP2A expression correlates with HPV16 E7 
immunoreactivity, both in regards to location of the expression and of 
immunointensity. Liu et al. (2011a) demonstrated that depletion of HPV16 E7 in 
cervical cancer cells downregulates CIP2A expression both at mRNA and protein 
level, indicating that HPV16 E7 may regulate CIP2A expression in cervical cancer.  
In neural tissue, CIP2A is expressed in the periventricular areas of the 
developing cerebrum, the region in which neural progenitor cells (NPCs) are located 
(Kerosuo et al. 2010). The proportion of self-renewing neural progenitor cells varies 
with CIP2A expression. Kerosuo et al. (2010) suggest that CIP2A plays a role in the 
self-renewal of neural progrenitor cells both during embryonic development and in 
adulthood, which at least to a certain degree is explained by the increased MYC 
signalling.  
In rheumatoid arthritis, Lee et al. (2011) demonstrated overexpression of 
CIP2A in fibroblast-like synoviocytes and synovial tissues in comparison to that in 
ostheoarthritis. CIP2A mRNA expression correlates with the aggressive 
histopathological grade of synovial tissue, notably with synovial hyperplasia.  CIP2A 
mRNA and protein overexpression has, similarly, been demonstrated in the bone 
marrow of acute myeloid leukaemia (AML) patients, where 77% of newly diagnosed 
AML and 71% of relapsed AML cases were positive for CIP2A (Wang et al. 2011).  
In HL60 human AML cells, CIP2A depletion induced partial differentiation into late 
promyelocytes, suggesting a potential therapeutic target (Li et al. 2008, Wang et al. 
2011). In chronic myeloid leukaemia (CML), high CIP2A protein levels in 
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mononuclear cells taken at diagnosis predict progression into blast crisis (Lucas et al. 
2011).  
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6. AIMS OF THE STUDY 
 
The purpose of the study was to evaluate the prognostic role of cancerous inhibitor of 
protein phosphatase 2A (CIP2A) in solid cancers. The study was limited to gastric, 
serous ovarian, tongue, and colorectal carcinomas.  
 
The specific aims of the study were to determine: 
 
1. The significance of CIP2A in prognostic evaluation – for this purpose the 
expression of CIP2A in the cancer specimens was studied by 
immunohistochemistry and immunoreactivity evaluated 
2. Association of CIP2A with other biomarkers, such as MYC, that could explain 
any alteration in prognosis 
3. Regulation of CIP2A expression in order to gain insight in the signalling 
pathways that lead to alterations in prognoses 
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T2N0M0. All patients were treated with curative intent between 1992 and 2002 at the 
Helsinki University Central Hospital according to the guidelines of the tumour board 
meeting. Detailed patient characteristics have been described (Keski-Säntti et al. 2006, 
2007). Preoperatively, 35 (48%) tumours were clinically classified as T1, and 38 
(52%) as T2. Following resection for cure of that primary tumour, 31 patients 
received no further treatment, whereas 42 underwent elective neck treatment (neck 
dissection, 9; neck dissection and radiotherapy, 32; radiotherapy only, 1). In elective 
neck dissection, primary lymph node positivity (pN+) was evident in 14 cases. During 
follow-up, 10 developed neck recurrences apparently representing late lymph node 
metastases without a primary recurrence. Median age at diagnosis was 59 (range 23-
95), and median follow-up of patients at study end was 7.9 years (range 0.3-17.2). 5-
year overall survival for the whole cohort was 68.5% (95% CI 57.9-79.1).  
7.1.4. Study IV 
Between 1989 and 1998, 643 consecutive colorectal cancer patients treated at the 
Department of Surgery, Helsinki University Central Hospital, entered Study IV 
(referred to as the “test set”). Of these, 92 (15%) belonged to a Dukes A group, 224 
(36%) to Dukes B, 162 (26%) to Dukes C, and 145 (23%) to Dukes D. Tumours were 
located mostly in the colon (55%; n = 341). Median age of the study population was 
65. Median follow-up time at the end of follow-up was 4.7 years (range 0-24.7), with 
a 5-year disease-specific overall survival of 54.4% (95% CI 50.5-58.3). For validation, 
we used a later dataset, which comprised 220 colorectal cancer patients treated from 
1998 to 2000. 33 (15%) were staged as Dukes A, 70 (32%) as Dukes B, 70 (32%) as 
Dukes C, and 45 (21%) as Dukes D. The majority of the tumours were located in the 
rectum: 129 (59%). Median age was 67, with a median follow-up time of 6.0 years 
(range 0-13.2) and a 5-year disease-specific overall survival of 64.8% (95% CI 58.1-
71.5). 
 
7.2. Tumour tissue specimens 
Tumour samples were fixed in buffered 10%-formalin solution, embedded in paraffin, 
and stored at the Department of Pathology, Helsinki University Central Hospital. 
Experienced pathologists reviewed all tumour samples from H&E stainings and 
indicated representative areas for microarrays. In Study I, a technical assistant 
punched three 0.6-mm cores with a tissue microarray instrument (Manual Tissue 
Arrayer 1, Beecher Instruments, Silver Spring, MD USA) and arranged them into 
paraffin as tissue-array blocks (Linder et al. 2006). In Study II, four representative 
0.8-mm cores, in Study III, six 1.0-mm cores, and in Study IV, three 1.0-mm cores 
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were retrieved (Kononen et al. 1998, Kallioniemi et al. 2001, Torhorst et al. 2001). In 
addition, in Study III, whole sections from seven tumour specimens of the nine cases 
in which all array cores were missing or included no tumour tissue were stained.  
In Study II, three human and three mouse ovarian tissue specimens were 
collected as normal controls, whereas in Study III, 37 representative specimens came 
from normal oral mucosa, dysplastic mucosal lesions, and invasive oral carcinoma.  
 
7.3. Immunohistochemistry 
Prior to immunohistochemical staining, the tissue blocks were freshly cut into 4-µm 
thick sections, fixed on slides, and dried for 12 to 24 hours at 37°C. The sections 
underwent deparaffinization in xylene, followed by rehydration through graded 
ethanol and distilled water. The sections were kept in Tris-HCl (pH 8.5) or Tris-
EDTA (pH 9.0) buffer for 20 minutes at 98°C in a PreTreatment module (Lab Vision 
Corp., Fremont, CA, USA) for antigen retrieval. We stained the sections in an 
Autostainer 480 (Lab Vision Corp.) with the Dako REAL EnVision Detection System, 
Peroxidase/DAB+, Rabbit/Mouse kit (Dako, Glostrup, Denmark). Sections were first 
treated for 5 minutes with 0.3% Dako REAL Peroxidase-Blocking Solution to block 
endogenous peroxidases. A rabbit polyclonal CIP2A antibody (Dako REAL Antibody 
Diluent) served for one hour (Soo Hoo et al. 2002) at room temperature as the 
primary antibody in all studies. Alternative primary antibodies were the mouse 
monoclonal MYC antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 
Studies I, III-IV) and rabbit polyclonal CIP2A antibody (Novus Biologicals, Littleton, 
CO, USA; Study II). Subsequently, a 30-minute incubation with peroxidase-
conjugated Dako REAL EnVision/HRP, Rabbit/Mouse reagent followed, after which 
visualization was developed with Dako REAL DAB+ Chromogen for 10 minutes. 
Between each pair of steps in the staining procedure, sections were washed with PBS-
0.04%-Tween20. Meyer’s haematoxylin served for counterstaining, followed by a 10-
minute wash in tap water and mounting in aqueous mounting medium (Aquamount, 
BDH, Poole, UK).  
In Studies I, II, and IV, sections were stained for p53 with the mouse 
monoclonal DO-7 antibody, which recognizes both mutant and wild-type p53 proteins 
(1:300 in Study I, 1:100 in Study II, 1:50 in Study IV, Dako) as described (Victorzon 
et al. 1996a, Lassus et al. 2003, Böckelman et al. 2012). For Ki-67 (1:500), the rabbit 
polyclonal A0047 antibody served as the primary antibody (Dako) in Study I (Mrena 
et al. 2010), in Study II the dilution was 1:150 (Lassus et al. 2004), in Study III, 1:100 
(Häyry et al. 2010), and in Study IV the mouse monoclonal MIB-1 antibody (Dako)  
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was diluted 1:100. An overview of the antibodies used for immunohistochemistry and 
Western blotting is presented in Table 7.  
7.3.1. Scoring of samples 
Tumour specimens were scored independently by two researchers blinded to clinical 
status and outcome data. Cytoplasmic CIP2A immunopositivity was scored as 0 to 3 
based on intensity of cancer-cell immunoreactivity, and the one with the highest 
intensity served for further analysis. Negative immunoreactivity was scored as 0, and 
diffuse weak cytoplasmic positivity as 1. Moderately positive or focally strongly 
positive intensity was scored as 2, and homogeneously strong intensity as 3. 
Specimens with discordant scores underwent re-evaluation with a multiheaded 
microscope, and the consensus score served for further analysis.  
In Study II, CIP2A nuclear immunoreactivity was scored as negative (score 0) 
when <10% of the nuclei stained positive and as positive (score 1) when ≥10% of the 
nuclei were positive. In Study III, in addition to tissue microarray blocks, we 
collected histological specimens from normal oral mucosa, dysplastic lesions, and 
invasive carcinoma (n = 37). Cytoplasmic CIP2A immunoreactivity was scored from 
whole-tissue sections for hot-spot areas as described, and nuclear CIP2A 
immunoreactivity was evaluated for trend.  
 In Studies I and IV, MYC immunoreactivity was scored separately for 
cytoplasmic and nuclear expression. Cytoplasmic MYC immunoreactivity was scored 
for intensity in the same way as CIP2A expression. In Study I nuclear MYC 
immunoreactivity was scored as negative (<10%) or positive (≥ 10%), whereas in 
Study IV nuclear MYC expression was scored according to percentage of 
immunopositive nuclei (0%; 1-10%; 11-30%; 31-50%; 51-80%; >80%). In Study III, 
MYC immunoreactivity was scored separately for cytoplasma and nuclei as follows: 
score 0 represented immunonegativity, score 1 positivity in less than 30% of the cells, 
score 2 positivity in 30 to 50%, score 3 positivity in 50 to 80%, and score 4 positivity 
in more than 80% (Häyry et al. 2010).  
For p53 in Study I, nuclear positivity was evaluated as low (negative or ≤20%) 
or high (>20%) expression (Victorzon et al. 1996a). In Study II, 
immunohistochemical staining for p53 was regarded as aberrant when tumour cells 
showed excessive p53 (homogeneous moderate or strong nuclear immunopositivity in 
over 50%) or were completely negative for p53 (no staining in any of the tumour 
cells). The p53 expression was considered to be normal when tumours showed – 
similar to the situation in normal fallopian and ovarian epithelium – weak p53 
immunostaining (Lassus et al. 2003). In Study IV, nuclear p53 was evaluated by 
percentage of stained cells. No immunoreactivity was scored as 0, 1 to 10% as 1, 11
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to 49% as 2, and more than 50% as 3, and in the final analysis grouped as ≤10% and 
>10% (Böckelman et al. 2012). Regarding the proliferation index Ki-67 in Study I, 
immunoreactivity evaluated as <10% was representative of negative expression and 
≥10% of positive (Mrena et al. 2010). In Study II, nuclear Ki-67 was analysed as low 
(<10%), moderate (10 to 25%), or high (>25%) (Lassus et al. 2004), whereas in Study 
III we scored it as negative or very low (0 to 29%), low (30 to 49%), moderate (50 to 
79%), or high (≥80%) expression (Häyry et al. 2010). In Study IV, Ki-67 was scored 
as 0, 1 to 10% as 1, 11 to 49% as 2, and more than 50% as 3, and analysed as ≤10% 
and >10% (Böckelman et al. 2012). 
7.3.2. DNA flow cytometry 
Ploidity was analysed in Studies I and II according to the protocol for DNA flow 
cytometry (Hedley et al. 1983, Victorzon et al. 1996b, Jahkola et al. 1998, Lassus et 
al. 2006). The lowest peak represented the reference with a DNA index value of 1.00. 
DNA index values between 1 and 1.20 represented diploidy. The S-phase fraction 
(SPF) was calculated with the Cellfit program of the FACScan flow cytometer 
(FACScan, Becton Dickinson, Mountain View, CA, USA) or manually by a modified 
rectilinear method, with the lower SPF chosen. The number of nuclei analysed from 
each specimen was at least 10 000. The median SPF of 7.6% served as the cut-off 
level for statistical analysis.  
 
7.4. Cells 
Gastric and ovarian cancer cell lines for Studies I to II (Table 8) were cultured in 
RPMI-1640 cell culture growth medium supplemented with 10% fetal calf serum 
(PromoCell GmbH, Heidelberg, Germany), 2 mM L-glutamine, 100 μg/ml 
streptomycin, and 100 units/ml penicillin, (Bio Whittaker Europe, Verviers, Belgium), 
and maintained at 37°C at 5% CO2 in air. Squamous-cell carcinoma cell lines HSC-3 
and SAS for Study III were cultured in 1:1 Dulbecco’s modified Eagle Medium 
(glucose 4.5 g/l) together with Nutrient mixture F-12 Ham (Sigma-Aldrich Chemie, 
Steinham, Germany) supplemented with 10% fetal calf serum (PromoCell), 2 mM L-
glutamine, 1 mM sodium pyruvate (Sigma), 0.4 ng/ml hydrocortisone (Sigma), 100 
μg/ml streptomycin, 100 units/ml penicillin, and 250 ng/ml fungizone (Invitrogen, 
Carlsbad, CA, USA).   
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7.6. Small molecular inhibitor experiments 
The following signalling pathways were targeted: EGFR (AG-1478, Calbiochem, 
Darmstadt, Germany), ERK (PD98059, Calbiochem), JNK (SP600125, Calbiochem), 
and Notch (GSI, Calbiochem). Dimethyl sulphoxide (DMSO; Sigma) served as the 
control. The inhibitor concentrations were 5 to 20 μM, and total proteins were 
extracted after 6 to 48 hours. 
 
7.7. Protein extraction and Western blot analysis 
Total proteins were extracted in Radio-Immunoassay Precipitation (RIPA) lysis buffer 
(150 mM NaCl; 1% NP40, Igepal CA-630, Sigma; 1% sodium deoxycholate, Sigma; 
0.1% sodium dodecyl sulphate; 50 mM Trizma Base adjusted with HCl to pH 8.0; 1 
mM EDTA adjusted with HCl to pH 8.0, Sigma; Complete Mini protease inhibitor 
cocktail tablet, Roche Diagnostics GmbH, Mannheim, Germany) or with hot Laemmli 
sample buffer (60 mM Tris-HCl pH 6.8; 2% sodium dodecyl sulphate; 10% glycerol, 
Sigma). Cytoplasmic and nuclear fractions were prepared with the NE-PER nuclear 
and cytoplasmic extraction kit (Pierce Biotechnology Inc., Rockford, IL, USA). 
Protein concentrations were measured with the Bio-Rad DC Protein Assay (Bio-Rad 
Laboratories, Hercules, CA, USA) or with BCA Protein Assay Kit (Pierce). For 
Western blot analysis, 30 µg protein extracts were separated by 12% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
nitrocellulose membranes. Membranes were blocked with 5% non-fat milk in Tris-
buffered saline (TBS; 20 mM Trizma Base, Sigma; 150 mM NaCl dissolved in 
distilled water and adjusted with HCl to pH 7.5) containing 0.1%-NP40 (Igepal CA-
630, Sigma), and subsequently incubated with primary antibodies as indicated in 
Table 7 (p. 40-41). After incubation with the secondary antibodies conjugated with 
horseradish peroxidase, proteins were visualized with the SuperSignal West Femto 
Maximum Sensitivity Substrate or with the Proteome Grasp ECL Kit (both from 
Pierce).  
 
7.8. RNA extraction and qRT-PCR  
RNA was extracted with the RNeasy kit (Qiagen, Valencia, CA, USA) or the 
Nucleospin RNA/Protein extraction kit (Macherey-Nagel GmbH & Co. KG, Düren, 
Germany), and transcribed to cDNA with the M-MLV Reverse Transcriptase, RNase 
H Minus, Point Mutant cDNA synthesis kit (Promega Corporation, Madison, WI, 
USA). Next, cDNAs were amplified with quantitative real-time polymerase chain 
reaction (qRT-PCR) with Light Cycler (Roche) and SYBR Green PCR Master Mix 
Patients and methods 
44 
kit (Roche Diagnostics, Indianapolis, IN, USA). We used the following primer 
sequences (Sigma-Proligo, St Louis, MO, USA): CIP2A forward: 5´-
CTGGTGAGATAATCAGCAATTT-3´, and CIP2A reverse: 5´- 
CGAAACATTCATCAGACTTTTCA-3´. We used Jumonji, a protein that is also 
known as KDM3A (or formerly as JMJD1A) and is involved in chromatin regulation 
as a control for general transcription activity: Jumonji forward: 5´- 
CACCCTGTTGGCAATTCTTT -3´, and Jumonji reverse: 5´- 
GCCAACATTGGAGACCACTT -3´. TATA-binding protein (TBP) or β-actin 
expression levels served for normalization of transcript levels: TBP forward: 5´- 
GAATATAATCCCAAGCGGTTTG -3´, TBP reverse: 5´- 
ACTTCACATCACAGCTCCCC -3´, actin forward: 5´- 
CGAGCACAGAGCCTCGCCTTTGC-3´, actin reverse: 5´- 
CATAGGAATCCTTCTGACCCATG-3´. 
 
7.9. Cell viability assay 
Cells were plated (2 x 103 cells per well) on 96-well plates and subjected to siRNA 
transfection with Lipofectamine 2000 reagent (Invitrogen) as described (section 7.5). 
The resazurin-based CellTiter-Blue Assay (Promega) served for measuring the 
relative amount of viable cells after one to eight days at 544/590 nm in a FLUOstar 
OPTIMA Microplate Reader (BMG LABTECH, Inc., Durham, NC, USA).  
 
7.10. Cell proliferation assay 
Cells were plated (2 x 104 or 1 x 105 cells per well) on 6-well plates and subjected to 
siRNA transfection with Lipofectamine 2000 reagent (Invitrogen) as described 
(section 7.5). Six days post-transfection, cells were trypsinized and counted in a 
Bürker chamber or with the Beckman Coulter Counter Analyzer (Beckman Coulter, 
Fullerton, CA, USA).  
 
7.11. Soft agar assay 
Cells (1 x 104 per plate) were suspended 48 h after siRNA transfection in 1 ml of 
0.25% agarose (GellyPhor, EuroClone Spa, Pero, Italy) supplemented with 2 ml of 
complete culture medium. Their suspension was added on top of 1 ml of a 0.25% base 
layer in 6-well plates. Cells were stained with Giemsa (Sigma) after 8 to 12 days in 
agarose. We took representative pictures with a Leica MZFLIII microscope (Leica, 
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Hicksville, NY, USA) and counted the colonies with the ImageJ Software (Wayne 
Rasband, National Institutes of Health, Bethesda, MD, USA).  
 
7.12. Cycloheximide pulse chase (protein stability) experiment 
In Study I, scrambled or CIP2A siRNA-treated gastric cancer cells were subjected to 
cycloheximide treatment (100 µg/ml) for up to 120 minutes 72 h after siRNA 
transfection. Total proteins were immunoblotted for serine-62-phosphorylated MYC 
(S62-p-MYC), total endogenous MYC (MYC), CIP2A, and β-actin, and quantitated 
with the Image Quant TL (Amersham Biosciences) image analysis software. We 
normalized the relative values for MYC, which had first been normalized to actin, to 
the levels in non-cycloheximide-treated cells. The relative MYC levels were plotted 
on a scatter graph with the best-fit exponential curve. 
 
7.13. Preparation of mouse embryo fibroblasts  
In Study I, mouse embryo fibroblasts (MEFs) were prepared from E13.5 R26-
MYCERT2 mice by the standard technique. Embryos were separated from their yolk-
sacs, decapitated, and their internal organs were removed; carcasses were minced with 
a fixed-head cell scraper and trypsinized for 30 minutes at 37ºC. MEFs were collected 
by centrifugation, resuspended in culture media (DMEM) supplemented with 10% 
fetal calf serum, L-glutamine, and penicillin/streptomycin), and plated on 150-mM 
dishes. Cells were harvested after confluency, and aliquoted for freezing. Cells were 
denoted as passage one when thawed and maintained on a 3T3 protocol. We used 4-
hydroxytamoxifen (4-OHT; Sigma-Aldrich) at 100 nM to activate the MYC-ER 
protein.  
 
7.14. Cell cycle experiments 
In Study I, we synchronized AGS cells (1 x 105 per well) by serum starvation with 
0.5% fetal calf serum in RPMI-1640 for 48 h. Subsequently, cells were stimulated to 
re-enter the cell cycle by addition of RPMI-1640 supplemented with 10% fetal calf 
serum. Cells were arrested in the S-phase by an established thymidine/aphidicolin 
protocol (Sillje et al. 1999) by treatment with 2 mM thymidine (Calbiochem) for 14 h, 
leaving them to rest in 10% FCS in RPMI-1640 for another 12 h, after which 
aphidicolin (1.6 µg/ml, Calbiochem) was added for 12 h. Finally, cells were treated 
either with the MYC inhibitor 10058-F4 (Sigma) for 6 h, or analysed for CIP2A and 
cell cycle marker expression levels.  
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7.15. Statistical analysis 
Associations between CIP2A positivity and clinicopathologic variables or biomarkers 
were assessed by the chi-square and Fisher’s exact tests, and the correlation between 
different CIP2A antibodies with Spearman’s correlation test (IBM SPSS Statistics, 
versions 16.0-19.0 for Mac; SPSS, Inc., an IBM Company, Chicago, IL, USA). 
Overall survival was calculated from date of surgery to death, disease-specific overall 
survival from date of surgery to death from cancer, and disease-free (in Study II 
progression-free) survival from date of surgery to first recurrence. Patients who died 
of causes other than the disease were censored at the date of their death. Survival 
curves were constructed according to the Kaplan-Meier method and compared with 
the logrank test (IBM SPSS Statistics and StatView for Mac, version 5.0.1; SAS 
Institute, Inc., Cary, NC, USA) (Kaplan and Meier 1958, Mantel 1966). Multivariate 
survival analysis was performed with the Cox proportional hazard model according to 
the backward stepwise method. In Study I, statistical significance between different 
treatment groups in in vitro experiments was analysed by an unpaired nonparametric 







Figure 5. CIP2A expression in normal ovarian and tubal tissues by the commercial Novus 
anti-CIP2A antibody. CIP2A expression in A) mouse graafian follicle, B) at the ovarian surface 
epithelium, and C) in tubal tissues. CIP2A expression in D) human follicular granulosa cells, 
E) in the ovarian surface epithelium, and F) in tubal tissues as well as in the inclusion cysts 
(insert of F). Granulosa cells are indicated with asterisks and surface epithelial cells with 
arrowheads. Original magnification was 200x for A, 400x for C-D and F, and 630x for B and E. 
 
8.1.2. Characterization of CIP2A expression in normal and dysplastic lesions (III) 
In Study III, we collected specimens from 37 oral mucosal epithelial lesions and 
stained them with the original anti-CIP2A antibody (Soo Hoo et al. 2002). In normal 
oral mucosa, the basal cells showed negative or weakly positive cytoplasmic CIP2A 
expression, whereas nuclei showed it as homogenously positive (Study III: Figure 3). 
Cytoplasmic CIP2A expression tended to be higher in severe epithelial dysplasia than 
in mild dysplasia. Nuclear CIP2A expression, on the other hand, was low in severe 
dysplasia and was expressed to a greater extent in lesions with mild dysplasia. In 
invasive carcinomas, we noted, however, either low or high cytoplasmic CIP2A 
protein expression. 
 
8.2. Association of CIP2A with clinicopathologic characteristics (I-IV) 
The association of cytoplasmic CIP2A immunoreactivity with clinicopathologic 
characteristics (Tables 10 and 11, p. 50-51) and previously established biomarkers 
(Tables 12 and 13, p. 52-53) were analysed by the chi-square test. Cytoplasmic 







years; p = 0.013), male gender (p = 0.001), and, according to Laurén’s classification, 
intestinal histological type (p < 0.001, Table 10). In ovarian cancer (II), it was 
associated with low TNM stage (stages I-II; p < 0.001) and high grade (p < 0.001). In 
tongue cancer (III), CIP2A positivity was also associated with high grade (p = 0.009). 
In colorectal cancer (IV), CIP2A positivity was associated with differentiation grades 
II and III (p = 0.014 in the test dataset and p = 0.018 in the validation dataset, Table 
11).  
In ovarian cancer (II), CIP2A nuclear positivity was more frequent in young (p 
= 0.015) and low-stage patients (p = 0.023), as well as in those patients with low-
grade disease (p < 0.001) or in ones free from ascites (p = 0.049, Table 1 in Study 
IV).  
 
8.3. Association of CIP2A with other biomarkers (I-IV) 
CIP2A was, in ovarian (p < 0.001) and colorectal cancer (p = 0.042), associated with 
strong p53 immunopositivity (Tables 12 and 13). We found an association with high 
proliferation index and CIP2A expression in gastric (p < 0.001), ovarian (p < 0.001), 
and tongue cancer (p = 0.008), but not in colorectal cancer (p = 0.488). Aneuploidy 
was associated with CIP2A positivity in gastric (p < 0.001) and ovarian cancer (p < 
0.001). In gastric cancer, CIP2A was associated with high S-phase fraction (p < 
0.001). We studied the association between CIP2A and MYC protein expression in 
gastric cancer and in the validation dataset of colorectal cancer. In gastric cancer, we 
found an association between cytoplasmic MYC immunopositivity and CIP2A 
immunopositivity (p < 0.001), whereas in colorectal cancer we noted an association 
between CIP2A positivity and nuclear MYC immunopositivity (p = 0.018).  
 
8.4. Univariate survival analyses (I-IV) 
For survival analyses, we constructed Kaplan-Meier curves and compared them with 
the logrank test. In gastric cancer (I), 5-year cumulative overall survival was 15.9% 
(95% CI 10.0-21.8) for CIP2A-positive patients and 23.1% (95% CI 13.7-32.5) for 
those CIP2A-negative (p = 0.064, Figure 6A). In ovarian cancer (II), we counted the 
survival disease-specifically. Patients with strong CIP2A positivity had a 5-year 
survival of 31.7% (95% CI 24.8-38.6), those weakly CIP2A-positive of 42.4% (95% 
CI 35.5-49.3), and CIP2A-negative patients of 63.0% (95% CI 52.6-73.4, p < 0.001, 
Figure 6B). For tongue cancer (III), the overall 5-year survival for CIP2A-strongly 
positive patients was 59.4% (95% CI 42.4-76.4) and 74.4% (95% CI 60.7-88.1) for 
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Figure 6. Overall survival according to cytoplasmic CIP2A expression. A) Overall survival in 
gastric cancer patients (p = 0.063). B) Disease-specific survival in serous ovarian cancer 
patients (p < 0.001). C) Overall survival in T1N0M0 and T2N0M0 tongue cancer patients (p = 
0.027). D) Disease-specific survival in colorectal cancer patients (p = 0.270).  
 
colorectal cancer (IV), the 5-year disease-specific overall survival was 56.8% (95% 
CI 52.1-61.5) for moderately and strongly positive patients and 63.7% (95% CI 50.6-
76.8) for negative and CIP2A-weakly positive patients (p = 0.270, Figure 6D). In sum, 
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Figure 7. Disease-specific survival in ovarian cancer patients according to nuclear CIP2A (p 
= 0.013). 
 
In ovarian cancer, patients with negative nuclear CIP2A immunoreactivity had 
a 5-year disease-specific survival of 37.2% (95% CI 30.3-44.2), whereas it was 45.0% 
(95% CI 39.2-50.8) for those who showed nuclear positivity (p = 0.013, Figure 7). 
 
8.4.1. Stratified survival analyses for clinical subgroups (I, II, and IV, unpublished 
data) 
In gastric, ovarian, and colorectal cancer we did survival analyses for certain 
subgroups. In gastric cancer (I), CIP2A predicted poor survival in those patients with 	  
small tumours (≤ 5 cm) with a 5-year survival of 18.0% (95% CI 3.9-26.2) for those 
CIP2A-positive, compared to 47.0% (95% CI 30.9-63.5) for those negative for CIP2A 
(p = 0.001, Figure 8A). For gastric cancer patients with advanced disease (pT3-4), 5-
year survival for those CIP2A-positive was 8.0% (95% CI 3.0-13.2) and 15.0% (95% 
CI 5.9-23.7) for those CIP2A-negative (p = 0.044, Figure 8B). Among p53-
immunopositive gastric cancer patients, the 5-year survival was 7.0% (95% CI 0.4-
14.4) for CIP2A-positive and 23.0% (95% CI 6.9-39.3) for CIP2A-negative tumours 
(p = 0.017, Figure 8C).  
In stratified analysis for ovarian cancer patients (II) with optimal debulking 
surgery (residual tumour < 1 cm), 5-year survival for CIP2A-positive patients was 
60.4% (95% CI 52.4-68.4) and 94.4% (95% CI 87.0-1.02) for those CIP2A-negative 
(p < 0.001, Figure 9A). For patients with a low-stage disease (stage I-II), the figures 
were 64.0% (95% CI 54.4-73.6) for those CIP2A-positive, and 96.6% (95% CI 89.9-
1.03) for those CIP2A-negative (p < 0.001, Figure 9B). Among patients who received 
platinum-based chemotherapy combined with chemotherapeutics other than taxanes, 
the 5-year survival for CIP2A-strongly positive patients was 25.2% (95% CI 16.2-
34.2), was 48.3% (95% CI 36.9-59.7) for patients with weak CIP2A positivity, and 
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Figure 9. Overall disease-specific survival in serous ovarian cancer patients stratified by 
clinical subgroup. A) Disease-specific survival for ovarian cancer patients undergoing optimal 
debulking (residual tumour < 1 cm; p = 0.001), and B) with a low-stage disease (pT1-2; p < 
0.001). C) Disease-specific survival for patients who received platinum-based chemotherapy 
together with chemotherapeutics other than taxanes (p = 0.001), and D) for patients who 
received platinum-based chemotherapy in combination with taxanes (p = 0.024).  
 
patients who received platinum-based chemotherapy combined with taxanes, the 5-
year survival for those CIP2A-strongly positive was 43.3% (95% CI 30.6-56.0), was 
50.8% (95% CI 38.8-62.8) for those weakly positive, and 79.0% (95% CI, 62.1-95.9) 
for those immunonegative (p = 0.024, Figure 9D). 
In the colorectal cancer test series (IV), CIP2A showed no prognostic value in 
the stratified analyses for colon, rectal, male, and female cancer patients. For colon 
cancer patients, 5-year survival was 58.4% (95% CI 52.3-64.5) for those CIP2A-
moderately or strongly positive, compared to 60.5% (95% CI 43.1-77.9) for those 
who were negative or weakly positive for CIP2A (p = 0.874, Figure 10A). For rectal 
cancer patients, 5-year survival for those CIP2A-moderately or strongly positive was  



















30         22        19          6          2     
Years from diagnosis

















26         9          8          3           0     
Years from diagnosis















32         17        13         5          2     
Years from diagnosis






















24         15        14         5         0     
Years from diagnosis
211        98        66        27       7
0              5            10           15           20            25 0              5            10           15           20           25


























and strong pos:  
Figure 10. Overall disease-specific survival in colorectal cancer patients (test series) stratified 
by clinical subgroup. A) Disease-specific survival for colon cancer patients (p = 0.874), and B) 
rectal cancer patients (p = 0.071). C) Disease-specific survival for male (p = 0.54), and D) 
female (p = 0.067) colorectal cancer patients.  
 
or weakly positive (p = 0.071, Figure 10B). Among male colorectal cancer patients, 
the 5-year survival was 59.0% (95% CI 52.7-65.3) for those CIP2A-moderately or 
strongly positive and 48.9% (95% CI 28.3-69.5) for those with CIP2A-negative or 
weakly positive tumours (p = 0.540, Figure 10C). For women, the figures were 53.9% 
(95% CI 47.0-60.8) for those with CIP2A-moderately or strongly positive, and 76.0% 
(95% CI 60.5-91.5) if CIP2A-negative or weakly positive (p = 0.067, Figure 10D). 
8.4.2. Prognostic role of MYC (IV and unpublished data) 
In gastric cancer, 5-year cumulative overall survival for patients with cytoplasmic 
MYC-immunopositive tumours was 36.2% (95% CI 22.7-49.7) and for the MYC-
negative, 30.2% (95% CI 23.1-37.3, p = 0.55, Figure 11A). The 5-year survival for 
those nuclear MYC-positive was 41.9% (95% CI 20.7-63.1) compared to 30.3% (95% 
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Figure 11. Overall survival according to MYC immunoreactivity. A) Overall survival in gastric 
cancer patients according to cytoplasmic MYC immunoreactivity (p = 0.55) and B) nuclear 
MYC immunoreactivity (p = 0.22). C) Disease-specific survival in colorectal cancer patients 
according to cytoplasmic MYC immunoreactivity (p = 0.003) and D) nuclear MYC 
immunoreactivity (p = 0.74).  
 
11B). In the validation dataset of colorectal cancer, the 5-year disease-specific 
survival for patients with tumours negative for cytoplasmic MYC immunoreactivity 
was 44.4% (95% CI 30.5-58.3), compared to 69.6% (95% CI 61.8-77.4) for those 
with cytoplasmic positivity of MYC (p = 0.003, Figure 11C). Nuclear MYC 
immunoreactivity showed no prognostic significance. The 5-year cumulative disease-
specific survival for patients with nuclear MYC immunopositive tumours was 61.2% 
(95% CI 52.6-69.8) and with MYC negative, 73.0% (95% CI 60.7-85.3, p = 0.74, 
Figure 11D). 
8.5. Multivariate survival analyses (I-IV) 
In gastric cancer (I), age, gender, stage, grade, Laurén’s classification, CIP2A 
expression, p53 expression, proliferation index, DNA ploidy, and MYC expression 
were entered into the multivariate survival analysis. TNM stage and ploidy were 
independent prognostic factors. In ovarian cancer (II), age, TNM stage, grade, 
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residual tumour size, and p53 expression have previously been found to show 
independent prognostic value (Lassus et al. 2003). When CIP2A expression was 
included, it added no prognostic information. In tongue cancer (III), age, gender, 
tumour size (pT-classification), grade, tumour invasion depth, proliferation index, and 
CIP2A expression were included. Age, tumour size, and CIP2A expression remained 
as independent prognostic factors. Multivariate survival analysis was performed in 
colorectal cancer (IV) for the test dataset with the following variables: age, gender, 
Dukes classification, grade, histological type, tumour location (colon or rectum), p53 
immunoreactivity, proliferation index, and CIP2A expression. Age and Dukes 
classification remained as independent prognostic factors (data not shown).  
 
8.6. CIP2A mRNA and protein expression in vitro (I and unpublished data) 
CIP2A protein was expressed at high levels in gastric cancer cell lines (AGS) of 
intestinal (MKN-28) and diffuse type cancers (MKN-45, TMK-1, and KATOIII), as 
well as in ovarian cancer cells (OV-4, OVCAR-3, CaOV3, ES-2, of which EFO-27 is  
!
Figure 12. CIP2A mRNA and protein expression. A) CIP2A protein expression in gastric, 
ovarian, and tongue cancer cell lines. B) Relative CIP2A mRNA expression in gastric and C) 
ovarian cancer cell lines. D) CIP2A expression in cytoplasmic and nuclear protein fractions in 
ovarian adenocarcinoma cells. Lamin served as a nuclear-positive control and "-tubulin as 
cytoplasmic positive control.  
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of mucinous type, and SKOV-3 of serous type) and squamous cell carcinoma from 
the tongue (HSC-3 and SAS; Figure 12A). At mRNA level, CIP2A was expressed in 
gastric and ovarian cancer cell lines to a significantly higher extent than is HT-1080, a 
fibrosarcoma cell line with previously demonstrated high CIP2A mRNA expression 
levels (Figure 12B and 12C; Junttila et al. 2007). In ovarian cancer cells, CIP2A 
protein was evident in both cytoplasmic and nuclear protein fractions (Figure 12D).  
 
8.7. Effect of CIP2A on proliferation (I) 
In gastric cancer cells, we studied the effect of CIP2A depletion on cell proliferation 
and found a decreased proliferation of CIP2A siRNA-treated MKN-28 cells in an 
eight-day experiment (p = 0.004 at day 8, Mann-Whitney U-test, Figure 13A). The 
effect of CIP2A depletion on proliferation was evident also in KATOIII (p < 0.001) 
and AGS cells (p = 0.015, Mann-Whitney U-test, Figure 13B). We further studied the  
 
 
Figure 13. Effect of CIP2A on proliferation. A) Effect of CIP2A siRNA on proliferation of MKN-
28 cells. Cells were transfected with CIP2A siRNA or scrambled siRNA. Proliferation was 
detected by a fluorometric cell viability assay. The mean from six samples with SEM is plotted. 
B) Effect of CIP2A siRNA on proliferation of MKN-28, KATOIII, and AGS cells. Proliferation at 
day 6 post-transfection measured by a fluorometric cell viability assay. The mean from 10-12 
samples with SEM is shown. C) Effect of CIP2A siRNA on anchorage-independent growth in 
MKN-28. CIP2A or scrambled siRNA-treated cells were stained with Giemsa after 8 or 12 
days of growth and colonies were counted. The mean of eight samples with SEM is shown.  
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role of CIP2A in malignantly transformed cells on semisolid agar and demonstrated 
that CIP2A depletion by siRNA inhibited anchorage-independent growth in MKN-28 
cells (p = 0.017 at day 8, Mann-Whitney U-test, Figure 13C).  
 
8.8. Effect of CIP2A on MYC stability (I) 
In gastric cancer AGS cells, CIP2A depletion by siRNA significantly inhibited the 
steady-state MYC protein expression (Figure 14A). The active S62-phosphorylated 
steady-state MYC protein was also inhibited as a result of CIP2A depletion (Figure 
14B). We studied the half-life of endogenous MYC protein by treating the cells with 
cycloheximide, a protein synthesis inhibitor, for 0 to 120 minutes 72 hours after 
CIP2A siRNA transfection. The half-life of MYC in non-transformed cells is 
typically 20 to 30 minutes (Junttila and Westermarck 2007) and was measured at the 
time at which 50% of the MYC protein was remaining. In scrambled siRNA-treated 
AGS cells, the half-life of MYC was over 100 minutes reflecting the increased MYC 
protein stability in these transformed gastric cancer cells, whereas in CIP2A-depleted 
cells it was less than 50 minutes, indicating that CIP2A is necessary for increased 




Figure 14. Effect of CIP2A on MYC protein stability. A-B) Effect of CIP2A siRNA on CIP2A, 
MYC, and S62-phospho-MYC protein levels in AGS gastric cancer cells. CIP2A or scrambled 
siRNA-treated cells were harvested 72 hours posttransfection. C) Effect of CIP2A on 
endogenous MYC protein stability. 72 hours after CIP2A or scrambled siRNA-transfection 
cycloheximide was added for 0-120 prior to protein lysis. The fraction of MYC protein present 
compared to, after normalization to actin levels, the level in untreated cells. Best-fit 




8.9. Identification of a positive feedback mechanism between CIP2A and MYC (I) 
We noted that in AGS gastric cancer cells, CIP2A protein expression was inhibited as 
a result of MYC siRNA-transfection (Figure 15A). The similar effect of MYC 
depletion on CIP2A protein expression was noted in MKN-28 gastric cancer and HT-
1080 fibrosarcoma cells (Study I: Figure 4B and Supplementary Figure 3C). At 
mRNA level, the effect was similar with a significantly lower CIP2A mRNA 
expression after MYC depletion (p < 0.001, Mann-Whitney U-test, Figure 15B). This 
led us to study further the mechanism by which CIP2A and MYC regulate each 
other’s expression, revealing increased CIP2A mRNA expression upon activation of 
MYC in a conditionally active MYCER construct in mouse embryo fibroblasts 
(Figure 15C). 
 
Figure 15. Identification of a positive feedback mechanism between MYC and CIP2A. A) 
Effect of MYC siRNA on CIP2A protein expression in AGS gastric cancer cells. Proteins were 
harvested 72 hours posttransfection with MYC.1, MYC.2, CIP2A, or scrambled siRNA. B) 
Effect of MYC siRNA on CIP2A mRNA expression in AGS cells. Relative mRNA expression 
24 hours posttransfection with CIP2A, MYC, or scrambled siRNA. C) Effect of activating 
expression from a conditionally active MYC construct, MYCER, on CIP2A mRNA expression. 
Mouse embryo fibroblasts expressing MYCER were activated with 4-OHT treatment. Relative 
CIP2A mRNA levels are shown as means with 95% CI from three independent experiments.  
 
8.10. Inhibition of signalling pathways (unpublished data) 
In gastric cancer, we studied the effect of signalling-pathway inhibition on CIP2A 
expression in MKN-28 and KATOIII cells. Inhibition of the Notch signalling pathway 
by gamma-secretase inhibitor (GSI) did not affect CIP2A expression in MKN-28 and 
KATOIII cells (Figure 16). In KATOIII cells, inhibition of the epidermal growth 
factor receptor (EGFR) downregulated CIP2A protein at a modest level, however, an 
effect that could not be confirmed in MKN-28 cells. Inhibition of the c-Jun N-
terminal kinase (JNK) –signalling pathway resulted in a downregulation of CIP2A 
protein expression already occurred at 5 "M of SP600125 in MKN-28 and KATOIII 
cells. In MKN-28 cells, we noted modestly decreased CIP2A protein expression after 
inhibition of the extracellular signal-regulated kinase (ERK) –signalling pathway. In 





Figure 16. Effect of signalling pathway inhibition on CIP2A protein expression in MKN-28 and 
KATOIII gastric cancer cells. A) Effect of Notch (GSI), EGFR (AG-1478), B) JNK (SP600125), 
and ERK (PD98059) signalling pathway inhibitors on CIP2A protein expression in MKN-28 
cells, and in C-D) KATOIII cells. Proteins were harvested after 24 hours.  
 
In ovarian cancer, we noted a downregulation of CIP2A protein expression after 
inhibition of EGFR in EFO-27 and CaOV3 ovarian cancer cells (Figure 17A). By 
inhibiting EGFR in EFO-27 cells, CIP2A was already downregulated after 24 hours, 
and this effect was sustained for at least 72 hours, as shown in Figure 17B. Inhibition 
of EGFR in the tongue cancer squamous cell carcinoma cells HSC-3 and SAS 
confirmed the downregulation of CIP2A protein expression noted in ovarian cancer 
(Figure 17C-D). Further, we demonstrated that an alternative inhibition of EGFR by 
siRNA also downregulated CIP2A protein expression in these tongue cancer cells 






Figure 17. Effect of EGFR inhibition on CIP2A protein expression in ovarian and tongue 
cancer cells. A) Effect of EGFR inhibitor (AG-1478) on CIP2A protein expression in EFO-27 
and CaOV3 ovarian cancer cell lines. Proteins were harvested after 48 hours. B) Time-
dependent effect of the EGFR inhibitor on CIP2A protein expression in EFO-27 cells. EFO-27 
cells were treated with 10 #M AG-1478 for 6 to 72 hours. C) Effect of AG-1478 on CIP2A 
protein expression in HSC-3 and SAS tongue cancer cell lines. Proteins were harvested after 
24 hours. D) Time-dependent effect of the EGFR inhibitor on CIP2A protein expression in 
HSC-3 and SAS cells. Tongue cancer cells were treated with 10 #M AG-1478 for 6 to 24 
hours. E) Effect of EGFR siRNA on CIP2A protein expression in tongue cancer cells. EGFR 






9.1. Expression of cytoplasmic CIP2A in cancer 
We found CIP2A immunopositivity to be detectable at high frequency levels in all 
cancers studied. In gastric cancer patients (n = 223), CIP2A was immunopositive 
(scores 1-3) in 65% and in ovarian cancer (n = 524) in 83%. In tongue cancer (n = 71) 
CIP2A was moderately or strongly positive (scores 2 and 3) in 85% and in colorectal 
cancer (n = 752) in 88%. This high frequency of CIP2A protein expression in cancer 
specimens is in line with previous findings on gastric, lung, oral, oesophageal, and 
prostate cancers, where the occurrence of high CIP2A mRNA or protein expression 
has been over 80% (Li et al. 2008, Dong et al. 2010, Katz et al. 2010, Qu et al. 2010, 
Vaarala et al. 2010). Cytoplasmic CIP2A expression was in Studies I to IV scored 
from 0 to 3 according to staining intensity. In further analyses, the cut-off for 
grouping the CIP2A expression was determined separately for each cancer type. In 
gastric cancer (I), we analysed CIP2A protein expression as negative (score 0) versus 
positive (scores 1 to 3), and in serous ovarian cancer (II) as negative (score 0), weakly 
positive (score 1), and strongly positive (scores 2 and 3). In tongue cancer (III), very 
few specimens were completely negative, with most of the specimens expressing 
CIP2A strongly, and thus we grouped CIP2A expression into low expression 
representing scores 0 to 2 and high expression as score 3. In colorectal cancer (IV), 
we divided CIP2A expression according to score distribution into approximately two 
equal groups with negative and weakly positive CIP2A (scores 0 and 1) versus 
moderately and strongly positive CIP2A (scores 2 and 3).  
Grouping CIP2A expression individually for each cancer type was necessary, 
as CIP2A was expressed at such differing levels. Vaarala et al. (2010) analysed 
CIP2A immunopositivity (n = 59) in prostate cancer according to cytoplasmic 
intensity (scores 0-3) and grouped CIP2A as negative (scores 0-1) versus positive 
(scores 2-3) in further analyses, whereas Katz et al. (2010) found cytoplasmic CIP2A 
to be strongly positive (score 3) in all oral cancer specimens studied (n = 8). In short, 
CIP2A is generally expressed to a relatively high extent in cancers, but the optimal 
cut-off level must be determined as to specific cancer types. In future studies, the 
most convenient way of analysing CIP2A would be to analyse data as 
immunonegative versus immunopositive; this may, however, depending on CIP2A 
expression level, be unsuitable for obtaining biologically relevant results regarding 




9.2. Expression of cytoplasmic CIP2A in normal tissues 
Relatively few studies have addressed CIP2A expression in normal tissues, and 
results are conflicting. In specimens from normal mouse and human female 
reproductive organs (II), we found that CIP2A was expressed strongly in the follicular 
granulosa cells and in the tubal surface epithelium, which is regarded as the normal 
equivalent of serous epithelium. The debate regarding tissue of origin of ovarian 
cancer is ongoing. It has been suggested that ovarian epithelial tumors arise from 
tissues that have their origin in the Müllerian ducts (Dubeau 2008). Interestingly, 
CIP2A was strongly expressed in inclusion cysts, which are regarded as one of the 
main origins of ovarian carcinomas.  
In normal cervical tissue, in cervical intraepithelial neoplasia (CIN) I, and in 
CIN II lesions, CIP2A expression was negative, whereas in CIN III specimens CIP2A 
was positive in 12.5%, and in cervical cancer specimens in 52.8% (Liu et al. 2011a). 
In oesophageal cancer, of 40 specimens, CIP2A mRNA was overexpressed in the 
cytoplasm of 36 (90%) when compared to the non-cancerous adjacent tissue, where 
CIP2A was expressed in only 8 (20%) (Qu et al. 2010). Ren et al. (2011) 
demonstrated in renal cell cancer that CIP2A mRNA was expressed at higher levels in 
cancer tissues than in matched adjacent tissues and normal tissues. CIP2A showed 
immunopositivity in 70% of renal cell cancer specimens, in 32% matched adjacent 
tissues, and in 17% nonmalignant renal tissues obtained from renal hamartomas. In 
gastric mucosal specimens adjacent to malignant lesions (I), we found that non-
malignant tissue is generally negative for CIP2A, with the exception of proliferating 
cells at the bottom of the gastric crypts (data not shown). Adjacent tissues from cancer 
patients are sometimes considered representative of normal tissue when other non-
malignant tissues are difficult to obtain. These non-cancerous adjacent tissues, 
however, may express genetic mutations similar to those in malignant tissues, and 
hence may not reflect the expression level in normal tissues. Although comparing 
expression in malignant tissues with that in adjacent tissues is not optimal, adjacent 
tissues may prove valuable when healthy human tissues cannot be resected for pure 
research purposes. In normal, dysplastic, and carcinoma specimens from the oral 
cavity (III), we noted an increase in the cytoplasmic CIP2A expression with 
increasing invasive morphology, whereas nuclear CIP2A expression tended to 
decrease with increasing invasive morphology. Junttila et al. (2007) found in most 
normal tissues very low levels of CIP2A mRNA. Taken together, these studies 
suggest that CIP2A is expressed at undetectable or low levels in normal tissues; 
however, certain female cell types from reproductive organs showed strong CIP2A 




9.3. Cytoplasmic CIP2A and clinicopathologic associations 
In gastric cancer (I), cytoplasmic CIP2A immunopositivity was associated with an 
intestinal type of cancer according to Laurén’s classification, which is usually 
associated with better prognosis than for diffuse tumours. In ovarian cancer (II), 
CIP2A positivity was associated with low TNM stage and high grade, and in tongue 
cancer (III), with high grade. In colorectal cancer (IV), CIP2A positivity was 
associated with differentiation grades II and III. In oesophageal cancer, no association 
between CIP2A immunopositivity and differentiation status has been demonstratable 
(Qu et al. 2010). In breast cancer, on the other hand, CIP2A is associated with high 
Scarff-Bloom-Richardson grade and lymph node positivity (Come et al. 2009), and in 
prostate cancer with high Gleason score (Gleason scores 7-10) (Vaarala et al. 2010).  
In our study, high proliferation index (Ki-67) was associated with CIP2A 
expression in gastric, ovarian, and in tongue cancer, but not in colorectal cancer. 
Dong et al. (2010) have demonstrated in non-small-cell lung cancer an association 
between CIP2A and high proliferation index, but in cervical cancer, no such 
association, nor any association with tumour size, differentiation status, node 
metastasis, nor clinical stage emerged (Liu et al. 2011a). Another study on lung 
cancer showed that CIP2A is associated with smoking and squamous cell histological 
type, but not with stage (Ma et al. 2011). In ovarian (II) and colorectal cancer (IV), 
CIP2A was associated with p53 immunopositivity. In breast cancer, CIP2A has been 
associated with proliferation markers and p53 mutations (Come et al. 2009). They 
further demonstrated, that in a breast cancer mouse model, CIP2A is strongly 
expressed in epithelial cancer cells with mammary gland-specific depletion of p53 
and either BRCA1 or BRCA2. In gastric cancer, we noted an association between 
CIP2A expression and high S-phase fraction. Based on these results, CIP2A is in 
several cancers associated with aggressive disease characteristics such as high grade, 
p53 immunopositivity, high proliferation index, and high S-phase fraction. In sum, 
cytoplasmic CIP2A immunopositivity may indicate an aggressive type of cancer that 
needs particular surveillance for recurrence or late metastasis.  
 
9.4. Clinical association between CIP2A and MYC 
Junttila et al. (2007) have shown that CIP2A inhibits protein phosphatase 2A and 
therefore keeps MYC phosphorylated and active. We found that CIP2A was 
associated with cytoplasmic MYC immunopositivity in gastric cancer (I) and with 
nuclear MYC immunopositivity in colorectal cancer (IV). In non-small-cell lung 
cancer, Dong et al. (2010) demonstrated an association between CIP2A mRNA 
expression and MYC mRNA expression. They also found a correlation between 
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CIP2A and MYC immunointensity. The stabilizing effect of CIP2A on the 
oncoprotein MYC, which is known to promote proliferation, may partly be the 
explanation of the aggressive behaviour of CIP2A-expressing cells. Furthermore, both 
oncoproteins are expressed during embryonal development in undifferentiated stem 
cells (Kerosuo et al. 2010). Cancer cells, as well as stem cells, express several genes 
important for cell proliferation, which may promote tumorigenesis. Kerosuo et al. 
(2010) demonstrate that CIP2A is involved in the maintenance of the self-renewing 
and proliferative identity of neural progrenitor cells, partly triggered by increased 
MYC signalling. Hence, one may conclude that the aggressive behaviour shown by 
cells expressing CIP2A is because of cancer stem cell-like characteristics. 
 
9.5. Role of CIP2A as a prognostic marker 
We found that cytoplasmic CIP2A immunopositivity was a marker of poor survival in 
serous ovarian (II) and early-stage tongue cancer patients (III). In tongue cancer, 
CIP2A was an independent prognostic marker, together with age and tumour size. 
This is in line with recent results on non-small-cell lung cancer, where CIP2A was 
demonstrated to serve as an independent prognostic marker (Dong et al. 2010). 
Interestingly, in ovarian cancer patients who underwent optimal debulking surgery or 
had low-stage disease (II), patients with CIP2A-positive tumours had a poor outcome, 
indicating that CIP2A may serve as a prognostic marker in these subgroups with 
otherwise favourable disease characteristics. In gastric cancer (I), we demonstrated 
that CIP2A serves as a prognostic marker in the subgroups of patients with small 
tumours, in advanced disease (pT3-4), and in p53-immunopositive tumours. Neither 
in colorectal cancer (IV) CIP2A showed no prognostic significance, nor did Come et 
al. (2009), regarding breast cancer, find any prognostic role for CIP2A. However, in 
female colorectal cancer patients and in the subgroup of patients with rectal tumours 
CIP2A-positivity was of borderline significancy for poor survival. Interestingly, 
Wangefjord et al. (2011) have proposed that in colorectal cancer, certain biomarkers 
may relate to sex hormone-status and found cyclin D1 to serve as a prognostic marker 
in men but not women.  
In conclusion, cytoplasmic CIP2A positivity revealed patients with poor 
outcome in certain, but not in all, cancers. Hence, to find, on the one hand, the 
optimal cut-off for studying the prognostic value of CIP2A and, on the other hand, to 
address the role of CIP2A as a prognostic factor in cancers, the clinical role of CIP2A 




9.6. Nuclear CIP2A expression 
The predominant cytoplasmic location of CIP2A that we noted has been demonstrated 
in several other studies (Soo Hoo et al. 2002, Junttila et al. 2007, Liu et al. 2011a). 
The clinical significance of nuclear CIP2A expression has been poorly addressed. In 
our studies, CIP2A protein was evident both in the cytoplasmic and in the nuclear 
compartments of cells. In ovarian cancer (II), the original anti-CIP2A antibody (Soo 
Hoo et al. 2002) recognized nuclear CIP2A in 59% of ovarian cancer specimens and 
cytoplasmic CIP2A in 83%, however, when we used the commercial CIP2A antibody 
(NB100-74663, Novus Biologicals), we found no nuclear CIP2A immunoreactivity. 
In contrast, Liu et al. (2011a) detected, by use of the same commercial antibody, 
CIP2A protein in normal cervix, in cervical intraepithelial neoplasia, and in cervical 
cancer specimens, in both cytoplasmic and nuclear compartments. Recently, several 
commercial CIP2A antibodies have become available. In ovarian cancer (II), positive 
nuclear CIP2A has been associated with low TNM stage and low grade, which 
contrasts with the positive cytoplasmic CIP2A that was associated with advanced 
TNM stage and high grade. We further demonstrated that negative nuclear CIP2A 
expression predicted poor outcome, suggesting that nuclear CIP2A expression may 
express different tumour behaviour than does cytoplasmic CIP2A. In ovarian cancer 
cells, we demonstrated CIP2A protein expression in both the cytoplasmic and nuclear 
compartments in all cell lines studied. The absence of CIP2A from the nuclear 
compartment may promote activation and transcription of pro-oncogenic genes such 
as MYC and hence, negative nuclear CIP2A may be associated with characteristics of 
an aggressive disease. In sum, nuclear CIP2A expression may play a role in tumour 
biology, a role that remains to be determined.  
 
9.7. Positive feedback mechanism between CIP2A and MYC 
CIP2A protein was expressed abundantly in all of our gastric, ovarian, and tongue 
cancer cell lines. CIP2A mRNA expression was also high in gastric and ovarian 
cancer cells. In Study I, we showed for the first time that depletion of CIP2A inhibits 
cell proliferation and anchorage-independent growth. This is in contrast with later 
findings by Ren et al. (2011) in renal cancer, where CIP2A depletion had no effect on 
proliferation. Inhibition of CIP2A reduced migration in a scratch migration assay and 
invasiveness in a Matrigel invasion assay (Ren et al. 2011). We further demonstrated 
that depletion of CIP2A downregulates MYC and, interestingly, that depletion of 
MYC downregulates CIP2A. When we further explored this mechanism between 
CIP2A and MYC, we noted that activation of MYC in a MYCER construct in mouse 
embryo fibroblasts resulted in increased CIP2A mRNA expression, and this led us to  
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propose a positive feedback regulation 
mechanism between MYC and CIP2A 
(Figure 18). The positive regulation of 
CIP2A by MYC that we demonstrated, 
and vice versa, may lead to a positive 
feedback loop ultimately enhancing 
MYC-mediated cellular responses and 
MYC’s oncogenic activity both in 
duration and strength. In CIP2A- and 
MYC-driven cancers, the CIP2A- and 
MYC-positive feedback loop may be a 
useful therapeutic target.  
Intriguingly, Eckhardt et al. (1994) 
have shown that depletion of MYC in 
HL60 cells induces cell differentiation. 
After the finding of Wang et al. (2011) 
in acute myeloid leukaemia that CIP2A 
depletion induces differentiation into 
promyelocytes, a question arises. Does 
the CIP2A depletion itself or does the 
decreased MYC expression resulting 
from the CIP2A depletion and the 
positive feedback mechanism between 
these two proteins serve as the trigger for the induced differentiation of HL60 cells? 
This mechanism, in which CIP2A depletion induces differentiation, should be a 
potential target for exploration of acute myeloid leukaemia therapy, with efforts to 
transfer the findings to solid cancers.  Furthermore, in chronic myeloid leukaemia, 
CIP2A serves as a predictive marker for progression into blast crisis; moreover, high 
CIP2A-levels prevent imatinib from JAK2-SET-mediated activation of PP2A, 
whereby MYC remains active, increasing the probability of subsequent genetic 
damage (Lucas et al. 2011). In hepatocellular carcinoma, CIP2A mediates AKT 
inactivation and apoptosis by bortezomib (Chen et al. 2010), an effect that enhances 
radiosensitivity and reduces tumour growth in vivo (Huang et al. 2011). That fact, 
together with the recent discovery of rabdocoetsin B, a natural compound functioning 
as the first small-molecular inhibitor of CIP2A that by inhibition of CIP2A and pAKT 
reduces apoptosis and promotes proliferation of lung cancer cells (Ma et al. 2011), the 
role of CIP2A-targeting therapies either alone or together with established 
chemoradiotherapeutic agents deserves more intense investigation.  
Figure 18. Positive feedback mechanism 
between CIP2A and MYC. MYC regulates, in 
addition to other target genes, CIP2A positively. 
When serine 62 (S62) dephosphorylation of MYC 
is prevented by CIP2A upregulation, MYC protein 
stability is enchanced. This leads in turn to an 
accumulation of the stable S62-phosphorylated 
MYC and hence, a further increase in CIP2A 
expression. The positive feedback between 
CIP2A and MYC may result in increased strength 
and duration of MYC -mediated cellular responses 
and oncogenic activity of MYC. 
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9.8. Regulation of CIP2A and potential clinical applications 
In order to investigate the oncogenic role of CIP2A and explore signal-transduction 
mechanisms possibly regulating CIP2A, we targeted four common signalling 
pathways. In our gastric cancer cells, inhibition of JNK in the MAPK signalling 
pathway resulted in a downregulation of CIP2A protein expression. Inhibition of 
Notch and ERK signalling pathways, however, gave inconsistent results regarding 
their effect on CIP2A protein expression. In gastric cancer cells, inhibition of EGFR 
resulted, however, in a modest depletion of CIP2A expression in KATOIII cells only, 
an effect that may be explained by a toxic concentration of the small-molecular 
inhibitor used. In EFO-27 and CaOV3 ovarian cancer cells, CIP2A protein at 24 hours 
after inhibition of EGFR, was already downregulated. The clearest effect was evident 
in tongue cancer cells, where CIP2A protein expression was reduced following EGFR 
inhibition by AG-1478; this was confirmed by an alternative inhibition by EGFR-
targeting siRNA. Inhibition of the EGFR signalling pathway in tongue cancer cells, 
seemed to downregulate CIP2A expression at protein level. These results are in line 
with the findings of Zhao et al. (2010), who recently demonstrated that CagA-
mediated overexpression of CIP2A is inhibited as a result of Src and MEK/ERK 
signalling-pathway inhibition. The phospho-CagA activates the MEK/ERK pathway 
and leads to an upregulation of CIP2A expression. In Study II, we demonstrated in 
ovarian cancer an association between CIP2A expression and EGFR protein 
overexpression and gene amplification. A partial co-localization of EGFR and CIP2A 
occurrs in oral squamous cell cancer tissues (Katz et al. 2010). Together with the 
finding that the ETS1 transcription factor mediates EGFR-MEK1/2-ERK-induced 
positive regulation of CIP2A (Khanna et al. 2011), our present and others’ results 
suggest that EGFR signalling may be an important step in CIP2A regulation, and thus 
EGFR-targeted therapy may function partly via the CIP2A oncoprotein.  
Recent findings show that CIP2A inhibits death-associated protein kinase 
(DAPk)-induced apoptosis and hence enhances cell survival (Guenebeaud et al. 2010). 
In the presence of CIP2A, PP2A cannot exert its effect on DAPk, which remains 
autophosphorylated and inactive, whereby no apoptosis is induced. In head and neck 
cancers, hypermethylation at the DAP-kinase gene promoter correlates with advanced 
disease and lymph-node metastases (Sanchez-Cespedes et al. 2000), whereas in 
gastric cancer (Chan et al. 2005) and hepatocellular carcinoma (Matsumoto et al. 
2003) loss of DAPk expression is associated with advanced stage and poor prognosis. 
The apparent oncogenic role of CIP2A and tumour suppressor role of DAPk, together 
with the interaction of these proteins at the UNC5H2/DAPk complex, suggest a 
potential clinically relevant association between CIP2A and DAPk; future studies 
should be planned to explore the role of this protein complex as a therapeutic target.  
Discussion 
74 
9.9. Strengths and limitations of this work 
Intra-tumoural heterogeneity may give rise to differences in staining intensity. This is 
a potential source of misinterpretation in the use of tissue array samples. However, 
results from tumour tissue microarrays obtained by accurate multiple sampling from 
histologically representative areas are in concordance with other biochemical and 
whole-section analysis (Kononen et al. 1998, Kallioniemi et al. 2001, Torhorst et al. 
2001). Tumour tissue microarrays are especially useful for research involving 
evaluation of large numbers of specimens. The advantage with our 
immunohistochemistry protocol using an immunohistochemical autostainer is that we 
were able to stain the relatively large clinical materials on a few slides in one set. Use 
of whole-section slides for the corresponding clinical materials would have required 
several staining series, and hence could have produced significant inter-series 
variation. The scoring method based on cytoplasmic intensity was established based 
on the initial, preliminary stainings in Study I, after which pre-defined scoring 
categories served for further data analyses. In the final analyses, the highest score for 
any of the TMA cores per specimen was chosen as representative for that patient. One 
may argue that the mean score for a histological section would serve as a better 
indicator of the biological role of a tumour marker than would the highest intensity 
score. However, it may well be that the highest score reflects tumour aggressivness 
more accurately. The cut-off for CIP2A expression was decided separately for all 
studies based on the distribution of CIP2A expression, as mentioned.  
Previous studies on ovarian cancer have suggested a distinct molecular 
pathogenesis and clinical manifestation for different histological types (Kobel et al. 
2008), and hence we decided to limit Study II to the serous histological type. In 
ovarian cancer, we validated our data by staining a subgroup of our clinical specimens 
with another commercial CIP2A antibody (NB100-74663, Novus Biologicals), and 
found a positive correlation between the CIP2A expression recognized by the original 
(Soo Hoo et al. 2002) and the commercial antibodies. In colorectal cancer, an earlier 
dataset served as the test set, and a later one for validation. By the use of the original 
CIP2A antibody, results for associations between CIP2A and clinicopathologic 
characteristics, as well as survival analyses, were in both datasets similar. These 
validations served to indicate that our results were independent of the antibody used 
and were sustained despite the datasets’ being from different time periods.    
Our relatively large ovarian cancer population with a long follow-up time 
unfortunately implies the heterogeneous treatment modalities of past decades. Median 
year of diagnosis was 1994, indicating that a significant proportion of the patients 
received the currently used platinum-based therapy in combination with taxanes. 
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Among such patients, CIP2A was a marker of poor outcome, demonstrating that the 
prognostic role of CIP2A is independent of the chemotherapeutic regimen. 
 
9.10. Concluding remarks 
What is of the utmost necessity, are new biomarkers to monitor therapeutic responses 
or detect early disease progression. Tumour auto-antigens such as p62 and p90/CIP2A 
may serve these purposes (Liu et al. 2011b). New biomarkers must be properly 
validated in large, prospective clinical trials for their prognostic and predictive value 
before conclusions can be drawn regarding benefits in individualized cancer treatment 
(Gangadhar et al. 2010). Based on our findings in a retrospective setting, CIP2A may 
serve as a prognostic marker in certain subgroups of gastric cancer patients, in serous 
ovarian cancer patients, and in early tongue cancer patients, but not in colorectal 
cancer patients. CIP2A is in some, but not in all solid cancers, associated with 
markers known to indicate an aggressive disease. Its clinical significance thus needs 
evaluation separately for each cancer.  
In future, the role of CIP2A as a predictive marker for recurrence and poor 
survival should be evaluated in order to select the patients for adjuvant treatment who 
need it most. CIP2A is found in haematological malignancies in mononuclear cells 
(Lucas et al. 2011), and efforts should be made to evaluate the role of CIP2A in solid 
cancers as a serum tumour marker. CIP2A is a potential therapeutic target, and 
antagonists of UNC5H/CIP2A or activators of the functional PP2A complex involved 
in mediated DAPk dephosphorylation may prove useful (Guenebeaud et al. 2010). 
Together with established chemoradiotherapeutic treatments such as bortezomib 
functioning via pAkt (Chan et al. 2010, Huang et al. 2011), inhibiton of CIP2A by the 
newly recognized rabdocoetsin B (Ma et al. 2011), may improve prognosis for 






Based on the four studies and previously unpublished data also presented here, CIP2A 
could recognize those with poor outcome among ovarian and tongue cancer patients. 
The association with high grade, p53, and MYC was evident in some cancers; thus, 
the clinical implication of CIP2A positivity demands separate evaluation for each 
cancer.  
 
1. CIP2A protein was expressed at high levels in gastric, serous ovarian, tongue, 
and colorectal cancer specimens. CIP2A served as a prognostic marker in 
certain subgroups of gastric cancer patients, in serous ovarian cancer, in early 
tongue cancer, but not in colorectal cancer, however, serving as an 
independent prognostic marker only for tongue cancer. The cut-off level for 
prognostic significance was cancer-type specific. 
2. Cytoplasmic CIP2A immunopositivity was associated in ovarian and tongue 
cancer with high grade. In addition, it was associated with characteristics of an 
aggressive disease, namely high proliferation index and p53 positivity. CIP2A 
was also associated with MYC in gastric and colorectal cancer.  
3. A positive feedback regulation mechanism between CIP2A and its target 
protein MYC in gastric cancer was recognized. Furthermore, depletion of 
EGFR by means of small interfering RNA and by the small-molecular 
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